Stockwinners Market Radar for November 01, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:11 EDT Cathie Wood's ARK Investment bought 101K shares of Roku today

20:09 EDT Cathie Wood's ARK Investment bought 332.6K shares of Unity today

19:52 EDT Freshpet names Todd Cunfer as new CFO - Freshpet (FRPT) "announced that Todd Cunfer has been named CFO, effective December 1, 2022. Todd previously served as CFO of The Simply Good Foods Company (SMPL). Dick Kassar, who has served as Freshpet's interim CFO since August 2022, will return to his prior role as Vice Chairman December 1, 2022. Freshpet also named Dirk Martin as Vice President of Customer Service & Logistics, effective December 7, 2022."

19:44 EDT Universal Stainless & Alloy reaches labor deal at Dunkirk - Universal Stainless & Alloy "announced that it has reached a new 3-year collective bargaining agreement with the hourly employees at its Dunkirk, New York, facility represented by Local 2693-01 of the United Steelworkers. The new 3-year collective bargaining agreement has been ratified by the bargaining unit and is effective as of November 1, 2022. The new contract maintains the flexible work rule terms and profit-sharing incentives."

19:01 EDT mCloud Technologies receives Nasdaq market value notification - mCloud Technologies announced it had received a written notification on October 26, 2022 from the Nasdaq Stock Market LLC indicating that the company's Market Value of Listed Securities for the last 30 consecutive business days was below the required minimum of $35M for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(2). The Notification Letter is only a notification of deficiency and has no immediate effect on the listing or trading of mCloud common shares. mCloud will continue to trade on Nasdaq under the symbol "MCLD." The company's common shares are also listed on the TSX Venture Exchange and the Notification Letter does not affect the Company's compliance status with such listing.

18:54 EDT Apple CFO sells $27.5M in common stock - In a regulatory filing, Apple disclosed that its CFO Luca Maestri sold 176.3K shares of common stock on October 28th in a total transaction size of $27.5M

18:23 EDT Eli Lilly CEO: Underlying fundamentals of the business are strong - In an interview on CNBC's Mad Money, David Ricks said the strong dollar was the reason behind the company's full year guidance cut. He said the company's recently launched type 2 diabetes drug, Mounjaro, showed a lot of promise. Most of its growth is coming from new patients, he added.

18:02 EDT CSL unit enters license agreement with Arcturus Therapeutics - CSL Limited (CSLLY) announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics (ARCT) to access their late stage self-amplifying mRNA vaccine platform technology. Arcturus Therapeutics is currently developing next generation mRNA vaccines. It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.

17:52 EDT Cheesecake Factory down 8% at $31.31 after Q3 earnings miss

17:37 EDT Clorox: FX headwinds now represent 2 point reduction in FY23 sales - For FY23: Foreign exchange headwinds now represent about a 2-point reduction in sales from 1.5 points assumed in the prior outlook. Gross margin increase of about 200 basis points, primarily due to the combined benefit of pricing, cost savings and supply chain optimization, offset by continued cost inflation. Selling and administrative expenses between 15% and 16% of net sales, including about 1.5 points of impact from the company's strategic investments in digital capabilities and productivity enhancements. Advertising and sales promotion spending of about 10% of net sales, reflecting the company's ongoing commitment to invest in its brands. Effective tax rate of about 24%, with year-over-year increase primarily reflecting lower excess tax benefits from equity compensation.

17:31 EDT Ryerson acquires Excelsior - Ryerson Holding announced its acquisition of Excelsior. Based in Fresno, California, Excelsior is a full-service fabrication and machining company with advanced processing capabilities including machining centers, laser and waterjet cutting, welding, and complex assemblies.

17:28 EDT Archrock, Enervest announce successful field pilot of methane capture technology - The company states: "Archrock and EnerVest announced the successful completion of a field pilot of Archrock's patent-pending methane capture technology on a United Production Partners gathering facility in the Barnett Shale. EnerVest is the contract operator for UPP. The field pilot comes following extensive testing of the technology in a lab setting. Archrock's methane capture device is a solution for fugitive emissions reductions from compressor operations, including unit blowdowns and compressor packings. The device is a skid mounted solution for natural gas powered and electric motor driven compressor packages for both existing compression facilities as well as greenfield locations."

17:18 EDT DuPont jumps 6% to $62.49 after termination of Rogers Corporation acquisition

17:15 EDT Rogers Corporation drops 38% to $141.98 after DuPont acquisiiton falls through

17:09 EDT ZoomInfo falls 22% to $34.05 after Q3 earnings and guidance

17:07 EDT Devon Energy sees Q4 production 640,000-660,000 boepd - The company said, "Due to the impact of acquisitions, Devon is revising its production forecast higher in the fourth quarter to a range of 640,000 to 660,000 Boe per day, a 6 percent increase compared to the year-ago quarter. This fourth-quarter volume growth will be driven by 35,000 Boe per day of incremental production from the company's Eagle Ford acquisition. The company also adjusted the midpoint of its upstream capital outlook to $835 million for the upcoming quarter. This guidance incorporates $120 million of incremental capital requirements related to recent bolt-on acquisitions in the Eagle Ford and Williston Basin."

16:53 EDT Quanex acquires LMI for $92M, sees acquistion as immediately accretive to EPS - Quanex Building Products announced the acquisition of substantially all the assets of LMI Custom Mixing or LMI for $92M, or $79M, net of the present value of $13M in anticipated future cash tax benefits. The transaction will be funded with cash-on-hand and borrowings on the Company's existing revolving credit facility. Quanex expects to realize approximately $500,000 in synergies in the first year following the acquisition. The Company expects LMI to generate revenue of approximately $80 million and an EBITDA margin of approximately 15% in fiscal 2023. LMI is a state-of-the-art custom polymer mixer that produces high-quality, customized rubber compounds used in a variety of applications in complementary and attractive diversified industrial end markets, including fenestration, where LMI has been a supplier to Quanex for approximately 20 years. Key Financial Benefits of the Combination: Attractive effective purchase price multiple; Immediately accretive to adjusted EPS;Improves consolidated margin profile.

16:51 EDT mCloud Technologies integrates with Google Cloud - mCloud Technologies (MCLD) announced it has implemented a new go-to-market plan on the back of its recent announcement it had entered a strategic partnership with Google Cloud (GOOG, GOOGL). As announced on October 27, this strategic partnership closely integrates and aligns the company with Google Cloud to jointly co-market, co-sell, and deliver AssetCare sustainability solutions to customers worldwide, starting with specific customers already working with both companies globally and in the United States, Canada, UK and Europe, Saudi Arabia, Malaysia, and Japan. These activities will widen the AssetCare business and expand mCloud's customer base. As a result of this integration, mCloud expects it will benefit from greater than 25% improvements to its cost structure beginning in calendar Q4 2022 and fully in place by end of Q1 2023. These optimizations include an approximate 25% reduction in headcount already implemented in Q3 2022, aligned with the company's exit from its Technical Project Services business, along with sustained improvements to costs associated with sales and marketing and research and development as these align with Google Cloud.

16:50 EDT Benefitfocus trading resumes

16:49 EDT Optex Systems awarded a $3.4M order to repair night vision equipment for Israel - Optex Systems Holdings announced it has been awarded a $3.4M order to repair and refurbish night vision equipment for the Government of Israel. The majority of this work will be performed in the Richardson facility in 2023.Danny Schoening, CEO, Optex Systems, Inc. stated "We are pleased to have been chosen by the Ministry of Defense to repair and refurbish their mission critical night vision equipment. Optex's unique experience with night vision equipment combined with our vertical integration allows Optex to efficiently complete these repairs in-house and bring them back to original equipment manufacturer's specifications."With this order, the current Optex backlog is in excess of $40M.

16:47 EDT Potbelly announces multi-unit development deal in Orlando - Potbelly announced a multi-unit development deal to bring six new shop locations to Orlando, Florida over the next seven years. As part of the Franchise Growth Acceleration Initiative announced in March, Potbelly plans to reach 2,000 units with at least 85% of those being franchised shops over the next 10 years. The brand also plans to refranchise approximately 25% of its corporate shops.

16:44 EDT NN, Inc. announces planned retirement of CEO Warren Veltman, engages Korn Ferry - NN, Inc. announced that its board of directors has implemented a management transition plan to address the planned retirements of Warren Veltman, president and CEO, and John Buchan, executive VP, Mobile Solutions and Power Solutions. NN anticipates that Veltman and Buchan will remain in their current positions until March 31, 2023, which may be extended in order to facilitate an orderly transition. Following their respective retirements, the company expects that Veltman and Buchan will remain available on a consulting basis to assist with the management transition as needed. The board has engaged Korn Ferry to assist in identifying candidates for the president and CEO position. In connection with the planned retirements, the company has named Gunars Vinkels as the interim COO of Power Solutions and Douglas Campos as the interim COO of Mobile Solutions. Each will report to John Buchan to facilitate a transition.

16:42 EDT Cocrystal Pharma granted European patent covering CC-42344 - Cocrystal Pharma announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus Replication," which covers the Company's broad-spectrum oral PB2 inhibitor CC-42344 in combination with approved influenza antiviral drugs including Tamiflu, Xofluza or Favipiravir. Cocrystal recently announced the completion of enrollment in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A, with topline study results expected later this year.

16:40 EDT NN, Inc. names Gunars Vinkels as Interim Oper Chief of Power Solutions - NN announced that its Board of Directors has implemented a management transition plan to address the planned retirements of Warren Veltman, President and Chief Executive Officer, and John Buchan, Executive Vice President, Mobile Solutions and Power Solutions. NN anticipates that Mr. Veltman and Mr. Buchan will remain in their current positions until March 31, 2023, which may be extended in order to facilitate an orderly transition. Following their respective retirements, the Company expects that Mr. Veltman and Mr. Buchan will remain available on a consulting basis to assist with the management transition as needed.The Board has engaged Korn Ferry, a global organizational consulting firm, to assist in identifying candidates for the President and Chief Executive Officer position, with expertise in the electrical and electric vehicle industries to further NN's focus on these rapidly growing markets. In connection with the planned retirements, the Company has named Gunars Vinkels as the interim Chief Operating Officer of Power Solutions and Douglas Campos as the interim Chief Operating Officer of Mobile Solutions. Each will report to John Buchan to facilitate a smooth transition and continuity of operational leadership.

16:39 EDT Mondelez announces three new members to senior management team - The company announced three new members of its senior management team. Frank Cervi has been named chief supply chain operations officer. Cervi most recently served as the company's head of supply chain strategy. Daniel Ramos has been named chief research and development officer, effective November 8. Ramos joins Mondelez (MDLZ) International from Estee Lauder (EL), where he had a strong focus on advancing sustainable packaging initiatives. Javier Polit, the company's chief digital and information officer, is now serving on the Mondelez International Leadership Team.

16:37 EDT Yum China says Covid continued to impact results in Q3 - "The COVID pandemic continued to impact the Company's operations and results in the third quarter. COVID-related health measures remained in effect across China, impacting travel and social activities. Despite the volatile environment, the Company grew system sales in the quarter by 5% year over year and outpaced the 2% national restaurant industry average for the period. We captured the growing demand for delivery and takeaway which offset the subdued dine-in volume. Same-store sales for the quarter recovered to the same level a year ago but remain below pre-COVID 2019 levels. From a timing perspective, same-store sales recovered sequentially in July and August, with August exceeding the prior year level. This is primarily due to lapping the Delta variant outbreak in the prior year period. However, same-store sales percentage declined year over year in September as preventive health measures were tightened. In September, on average, approximately 900 of our stores were temporarily closed or offered only takeaway and delivery services, compared to approximately 400 stores on average in July and August. Entering the fourth quarter, new infections continued to increase in October with resurgent outbreaks across China. In October, approximately 1,400 of our stores were either temporarily closed or offered only takeaway and delivery services. Nationwide, consumers are traveling less and reducing expenditures. According to government statistics, for the seven-day National Day holiday starting October 1, the number of travelers and related travel spending was down 18% and 26%, respectively, compared to the same holiday period last year. The COVID situations remain uncertain with regional outbreaks continuing to impact our operations. Against this backdrop, we will stay nimble with our contingency planning, ready to pivot with changing market conditions."

16:35 EDT ProPetro acquires Silvertip in cash and stock deal - ProPetro announced it has acquired Silvertip Completion Services Operating, a provider of wireline perforating and pumpdown services solely in the Permian Basin, creating a leading completions-focused oilfield services company headquartered in the Permian Basin. The transaction consideration consisted of the issuance of 10.1 million shares of ProPetro common stock, $30 million of cash, the payoff of approximately $7 million of assumed debt, and certain other transaction costs, subject to customary post-closing adjustments, which implies a value of $150 million based upon a 15-day volume weighted average price of ProPetro's stock price as of October 27, 2022. Sam Sledge, Chief Executive Officer of ProPetro, commented, "This acquisition represents another important step for ProPetro, advancing our strategy of pursuing accretive growth opportunities that expand our margins and increase free cash flow generation to create a stronger, more resilient and more diversified company. With our highly complementary service offerings including Silvertip's premier wireline franchise, strong cash flow metrics, and blue-chip customer relationships, ProPetro is now well-positioned to execute on cross-selling opportunities, while accelerating our ability to achieve our financial growth targets through a more integrated and diversified service offering. We are excited to welcome the Silvertip team as we work to deliver best-in-class services for our customers through a more integrated and diverse service offering to aid us in unlocking meaningful value for our shareholders." The Company acquired Silvertip for consideration of 10.1 million shares of ProPetro common stock, $30 million of cash, the payoff of $7 million of assumed debt, and certain other transaction costs, subject to customary post-closing adjustments, which implies a value of $150 million based upon a 15-day VWAP of ProPetro's stock price as of October 27, 2022. On a fully-diluted basis, Silvertip's former shareholders now own approximately 9% of ProPetro.

16:34 EDT Comstock Resources reinstates 12.5c per share quarterly cash dividend - Comstock's board approved the reinstatement of the company's quarterly cash dividend, with the first dividend to be paid in Q4, at an annual dividend rate of 50c per share, or 12.5c per quarter. Comstock last paid a common dividend in 2014. The fourth quarter dividend will be payable on December 15 to stockholders of record at the close of business on December 1.

16:32 EDT Cheesecake Factory board authorizes increase of 5M shares to buyback program - The company repurchased approximately 889,000 shares of its common stock at a cost of $26.7 million in the third quarter of fiscal 2022, and also announced that its Board of Directors declared a quarterly dividend of $0.27 per share to be paid on November 28, 2022 to shareholders of record at the close of business on November 15, 2022. As of September 27, 2022, 1.5 million shares remained available under the company's authorized share repurchase program. Subsequent to quarter-end, the company's Board of Directors authorized an increase of 5.0 million shares to the existing repurchase program raising the total authorization to 61.0 million shares.

16:31 EDT Cheesecake Factory expects to open up to 13 new restaurants in FY22

16:30 EDT Ambrx Biopharma names Daniel O'Connor as new CEO - Ambrx Biopharma "announced the appointment of Daniel O'Connor as Chief Executive Officer. Mr. O'Connor has over 23 years of executive experience and leadership in all aspects of the biopharmaceutical industry, including CEO leadership of two public oncology-focused companies, OncoSec Medical and Advaxis, Inc., as well as C-Suite leadership roles at ImClone Systems, Bracco Diagnostics, and PharmaNet, Inc. He has a proven record of accomplishment in oncology drug development, with a focus on business strategy, clinical execution, product development, business transformation and corporate development. He has overseen the successful initiation of several early phase oncology clinical trials, including combination trials with several different FDA approved checkpoint inhibitors. Additionally, he has led numerous life science licensing transactions and drug development collaborations with major pharmaceutical companies and has raised hundreds of millions in the capital marketplace."

16:27 EDT Liberty Global reiterates 10% buyback floor for 2023

16:22 EDT Horizon Technology raises monthly distributions, declares special distribution - Horizon Technology announced that its board of directors has declared a 10% increase in monthly cash distributions to 11c per share, payable in each of January, February and March 2023, and a special distribution of 5c per share payable in December 2022. The following tables show these distributions total 38c per share. Since its 2010 initial public offering, Horizon has paid a total of $197M in distributions to its shareholders.

16:20 EDT Assurant sees FY22 adjusted EBITDA ex-catastrophes modestly down to flat - Sees high single-digit growth in Adjusted earnings, excluding reportable catastrophes, per diluted share, driven by share repurchases.

16:17 EDT Benefitfocus trading halted, news pending

16:09 EDT Enovix announces advancements to Laser Technology Program - Enovix Corporation announced two major developments related to its laser program: a non-binding Memorandum of Understanding with IPG Photonics Corporation (IPGP), the leader in high-power fiber laser technology, to collaborate to develop cutting edge, next-generation laser tooling and methods to optimize battery cell manufacturing processes and productivity, and the appointment of Manuel Leonardo, an expert in the field of laser photonics, as Senior Staff Laser Engineer. Enovix believes these two developments will further accelerate its efforts to increase manufacturing productivity and product performance and enable the development of future products. The goals of the collaboration agreement with IPG and Enovix are to enable Enovix' growth model and promote the transition from mechanical cutting to laser processing in the industry at large. The next-gen laser tooling equipment is intended to significantly advance Enovix' efforts to scale. Enovix hired Manuel Leonardo to lead its laser photonics programs. He has been working with Enovix since April 2022 on its Technical Advisory Board.

16:08 EDT Exelixis, Sairopa establish development collaboration, option agreement - Exelixis and Sairopa announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPalpha. SIRPalpha expressed on myeloid cells interacts with CD47 present on the surface of cancer cells and blocks the ability of macrophages to clear tumor cells via phagocytosis and inhibits tumor antigen presentation to T-cells. Blocking SIRPalpha has the potential to improve the immune system's ability to attack tumors by addressing a significant immune-suppressive component of the tumor microenvironment. ADU-1805 is active against all human alleles of SIRPalpha, which may allow it to address a broader patient population than other SIRPalpha-directed therapies. ADU-1805 has also been optimized to bind preferentially to SIRPalpha vs. other SIRP family members, which may enhance its ability to stimulate immune cells. "ADU-1805 is a promising antibody that has been carefully optimized to maximize the potential benefit of blocking the SIRPalpha - CD47 checkpoint, while minimizing potential toxicities and allowing for treatment of the broadest population of appropriate patients. We believe that ADU-1805 represents a differentiated and potentially best-in-class approach to this pathway," said Peter Lamb, Ph.D., Executive Vice President, Scientific Strategy and Chief Scientific Officer, Exelixis. "With an Investigational New Drug filing anticipated in the first quarter of 2023, this agreement provides an exciting opportunity to expand our clinical pipeline. There is a strong scientific rationale for blockade of this pathway in multiple solid tumor types and for combining ADU-1805 with XL092, our novel tyrosine kinase inhibitor, and with approved immune checkpoint inhibitors, further expanding the potential clinical and commercial value of ADU-1805."

16:07 EDT Rigel reports results from FOCUS Phase 3 clinical trial of fostamatinib - Rigel Pharmaceuticals announced top-line efficacy and safety results from the FOCUS Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors. The trial approached but did not meet statistical significance in the primary efficacy endpoint of the number of days on oxygen through Day 29. All prespecified secondary endpoints in the study numerically favored fostamatinib over placebo, including mortality, time to sustained recovery, change in ordinal scale assessment, and number of days in the ICU. This multi-center, double-blind, placebo-controlled Phase 3 study, supported by the U.S. Department of Defense, enrolled 280 patients that were randomly assigned to either fostamatinib plus standard of care (SOC) (N=141) or matched placebo plus SOC (N=139). Treatment was administered orally twice daily for 14 days with a follow-up period to Day 60. The primary endpoint of this study was the number of days patients spent on supplemental oxygen through Day 29. Secondary endpoints were designed to assess mortality risk, patient improvement from severe disease, duration of hospitalization, and number of days in the ICU, as well as safety. There were no meaningful imbalances between treatment groups at baseline. Key findings from the Phase 3 clinical data readout include: The mean number of days on oxygen through Day 29 in the fostamatinib treatment arm was 6.9 days compared to 9.0 days in the placebo arm; by Day 29, in the overall population, there were 4 deaths in the fostamatinib group compared to 8 in the placebo group. Fostamatinib numerically reduced patient all-cause mortality by 50%; the mean change from baseline in clinical status score to Day 15 using the 8-point ordinal scale was -2.4 for fostamatinib and -1.9 for placebo.

16:00 EDT Marsh McLennan Agency acquires Focus Insurance, terms not disclosed - Marsh McLennan Agency, a subsidiary of Marsh, announced the acquisition of Focus Insurance, a personal insurance brokerage firm based in Houston, Texas. Terms of the acquisition were not disclosed. Founded in 2001, Focus Insurance specializes in customized personal insurance programs throughout the United States. All Focus employees, including Vice President at Focus Mickie Comiskey, will be joining MMA. "Focus Insurance puts individuals and families first, with a keen eye to customized solutions that protect their clients' interests and assets," commented Bill Henry, CEO of MMA's Southwest region. "We are pleased to welcome Focus to MMA as we see continued growth and expansion in the region."

15:55 EDT New York Attorney General announces agreement with Compass - New York Attorney General Letitia James announced she has reached an agreement with real estate brokerage, Compass Inc., to protect low-income tenants. "The Office of the Attorney General, with assistance from the Housing Rights Initiative, found that Compass real estate agents refused to process rental applications from low-income tenants in Manhattan because they had a Section 8 voucher, a violation of New York's laws that protect tenants against source of income discrimination. Under New York law, a lawful source of income for housing includes any form of federal, state, or local housing assistance, including Section 8 vouchers. As a result of today's agreement, Compass is required to waive any broker fees for the first 25 applicants with Section 8 vouchers, update its employee trainings, and post signage that they accept housing assistance vouchers," the AG's office stated in a press release. Reference Link

15:44 EDT Gravitas Education Holdings trading resumes

15:25 EDT Google debuts new shopping features to find deals easily from search - Shashi Thakur VP/GM, Consumer Shopping for Google blogged, in, part, earlier: "The holiday season is upon us, and many are already getting into the (shopping) spirit. Deals are particularly top of mind this year: Among Americans planning to shop for the holidays, 43% are planning to look for deals and sales more than last year. So we're sharing a few new features to help you easily find those discounts and get the perfect gift at the right price. Coupon codes are a great way to save, but finding them - and making sure they work - can be challenging. To help shoppers save money and time, we're bringing promotions front and center in product searches, Compare deals side by side. "If you search for a women's puffer coat, for example, we'll show you a side-by-side comparison of available puffer coat deals right in your results. Get price insights: "we're bringing our price insights feature to Search to help shoppers understand the prices they see and make better buying decisions." Other companies in the e-commerce space include: Etsy (ETSY), Amazon.com (AMZN), PayPal (PYPL) and MercadoLibre (MELI). Reference Link

14:48 EDT ShockWave announces final analysis from Disrupt PAD III Observational Study - Shockwave Medical announced that the final 1,373-patient cohort analysis from the Disrupt PAD III Observational Study "again demonstrates consistent IVL outcomes in complex and challenging lesions across multiple peripheral vessel beds." The study represents the largest prospective "real world" evidence supporting the treatment of complex, heavily calcified peripheral artery disease with IVL, stated the company, which notes that the final analysis was presented earlier today at VIVA22 in a late-breaking clinical trial session.

14:04 EDT Teleflex recalling several types of ISO-Gard Filter S, FDA says - Teleflex is recalling several types of the ISO-Gard Filter S after receiving reports that the filters may split or detach from breathing systems, the FDA announced. If the filter splits or detaches during use, the filter may not work properly or efficiently. The issue may cause a patient to receive an insufficient supply of air and for the patient's oxygen levels to drop below safe levels, as well as potential cross-contamination, the agency said in a statement. Use of these devices may cause serious injury or death, it said. Teleflex has reported that there have been 36 complaints and four injuries, including desaturation, related to this issue. Reference Link

13:14 EDT Upstart eliminates positions of 140 hourly employees given 'challenging economy' - Upstart said in a filing with the Securities and Exchange Commission that, "Given the challenging economy and reduction in the volume of loans on our platform, on November 1, 2022, we notified approximately 140 hourly employees who help process loan applications that their positions had been eliminated."

13:03 EDT electroCore, Joerns enter distribution partnership for gammaCore Sapphire - electroCore announced that gammaCore Sapphire, an FDA cleared non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare within select managed care health systems.

12:49 EDT Leidos received grand jury subpoena for California criminal investigation - Leidos disclosed in its quarterly filing that in September, it received a federal grand jury subpoena related to the criminal investigation by the U.S. Attorney's Office for the Southern District of California, in conjunction with the U.S. Department of Justice's Fraud Division. The subpoena requests documents relating to the conduct that is the subject of the company's internal investigation, and it is in the process of responding to the subpoena, Leidos said. The company discovered, in late 2021, activities by its employees, third party representatives and subcontractors, "raising concerns related to a portion of our business that conducts international operations." Leidos is conducting an internal investigation to determine whether the identified conduct may have violated the company's Code of Conduct and potentially applicable laws, including the U.S. Foreign Corrupt Practices Act. The company has voluntarily self-reported this investigation to the Department of Justice and the Securities and Exchange Commission and is cooperating with both agencies.

12:35 EDT Honda reports October U.S. sales down 16% to 81,545 vehicles - American Honda reported October sales of 81,545 units, down 16.0% from the same month of last year but the company's "best monthly performance since April despite ongoing supply and transportation issues." Reference Link

12:17 EDT Interactive Brokers reports October DARTs down 15% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for October. Brokerage highlights for the month included: 1.965 million Daily Average Revenue Trades, 15% lower than prior year and about even with prior month. Ending client equity of $296.7B, 22% lower than prior year and 3% higher than prior month. Ending client margin loan balances of $39.5B, 26% lower than prior year and 2% lower than prior month. Ending client credit balances of $95B, including $2.3B in insured bank deposit sweeps, 9% higher than prior year and about even with prior month. 2.04 million client accounts, 29% higher than prior year and 1% higher than prior month. 218 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.09 including exchange, clearing and regulatory fees.

12:01 EDT Catalent falls -25.6% - Catalent is down -25.6%, or -$16.81 to $48.92.

12:01 EDT Carvana rises 11.6% - Carvana is up 11.6%, or $1.56 to $15.10.

12:00 EDT Harsco rises 21.3% - Harsco is up 21.3%, or $1.12 to $6.41.

11:16 EDT ProFrac Holding to change ticker symbol to 'ACDC' on November 2 - ProFrac Holding Corp. announced that its Class A Common Stock will begin trading on NASDAQ under the ticker symbol "ACDC" prior to market open on November 2, 2022. This will replace the company's current ticker symbol, "PFHC," which has been used since its initial public offering in May 2022. Matt Wilks, ProFrac's Executive Chairman, commented, "Our acquisition of U.S. Well Services announced earlier today solidifies ProFrac's position as the industry leader in electric hydraulic fracturing, which we believe represents the future of the industry. By changing our ticker symbol to "ACDC," we want to commemorate our market leadership so investors can recognize that we own the industry's leading intellectual property portfolio that gave rise to electric frac technology with the market's first e-fleet deployment in 2014, which includes over 110 patents. Importantly, our ESG strategy will be greatly enhanced by reducing fuel costs and minimizing our emissions footprint. In today's environment, we believe electric frac fleets provide improved efficiency, lower R&M costs, greater value, and a lower overall cost of completion to our customer. We believe this a true win-win scenario for us, our investors, our customers, the environment and the communities in which we operate."

11:04 EDT MeridianLink, Auto Financial Group sign integration agreement - Auto Financial Group announced that it has signed an integration agreement with MeridianLink. This partnership further reinforces AFG's mission to pursue innovative solutions that help our clients streamline their workflows. With this integration, AFG's Balloon Lending Program will be even easier to implement for financial institutions using MeridianLink's loan origination system. The loan origination process will be more efficient, and users will not need to toggle between two platforms, increasing productivity and minimizing errors. Information will be updated automatically between both systems, keeping all loan documentation in sync and up to date.

10:56 EDT Enerpac Tool principal accounting officer resigns - In a regulatory filing, Enerpac Tool Group disclosed that on October 26, Bryan Johnson, the Vice President of Finance and Principal Accounting Officer of the company, submitted his resignation, effective as of November 1, as an officer and employee of the company due to a material reduction in the scope of his role and responsibilities as the result of changes implemented to flatten the company's organizational structure. "Johnson's resignation does not reflect any disagreement with or irregularities in the Company's accounting principles, practices, financial statements or disclosures," the company stated. On October 27, the company's board of directors appointed Anthony Colucci, the company's Executive Vice President and Chief Financial Officer, to also serve as the company's principal accounting officer.

10:28 EDT Cochlear announces FDA approval of Nucleus 8 Sound Processor - Cochlear Limited receives U.S. Food and Drug Administration approval for the Cochlea Nucleus 8 Sound Processor. The company said, "The Nucleus 8 Sound Processor is now the smallest and lightest behind-the-ear cochlear implant sound processor available in the industry. It is also the world's first cochlear implant sound processor ready to provide direct audio connectivity to everyday consumer electronics using the next generation LE Audio technology from Bluetooth."

10:13 EDT Mazda Motor reports October North America sales up 29.7% to 25,319 vehicles - Mazda North American Operations reported total October sales of 25,319 vehicles, an increase of 29.7% compared to October 2021. With 26 selling days in October, compared to 27 the year prior, the company posted an increase of 34.7% on a Daily Selling Rate, or DSR, basis.

10:08 EDT Custom Truck One Source, UTV International enter sales, service partnership - UTV International and Custom Truck One Source put the finishing touches on a brand-new partnership. Custom Truck One Source will welcome 6 new tracked utility vehicles from UTV International into its sales catalogue and rental fleet.With the final negotiations now in place, the UTV International / Custom Truck One Source partnership is up and running: offering broader national coverage and improved service response times in 34 states.

10:05 EDT Sysco not seeing recession concerns, signs of business slowdown - Comments taken from Q1 earnings conference call.

10:00 EDT Solaris Oilfield falls -14.5% - Solaris Oilfield is down -14.5%, or -$1.97 to $11.65.

10:00 EDT XPO Logistics falls -38.9% - XPO Logistics is down -38.9%, or -$20.14 to $31.60.

10:00 EDT Uber rises 16.2% - Uber is up 16.2%, or $4.30 to $30.87.

09:58 EDT Turquoise Hill postpones special meeting regarding Rio Tinto arrangement - Turquoise Hill Resources (TRQ) announced that pursuant to a request from Rio Tinto International Holdings Limited (RIO), the company has postponed to 10:30 a.m. on November 8, 2022 the special meeting of Turquoise Hill shareholders that was initially scheduled for November 1, 2022 to consider, and if deemed advisable, to pass the special resolution to approve the proposed statutory plan of arrangement, pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Rio Tinto will acquire the approximately 49% of the issued and outstanding common shares of Turquoise Hill that Rio Tinto and its affiliates do not currently own for C$43.00 per share in cash.

09:47 EDT Perfumania falls -8.6% - Perfumania is down -8.6%, or -94c to $10.05.

09:47 EDT XPO Logistics falls -37.9% - XPO Logistics is down -37.9%, or -$19.59 to $32.16.

09:47 EDT Uber rises 13.5% - Uber is up 13.5%, or $3.58 to $30.15.

09:46 EDT FBI reports 2.5M NICS firearm background checks in September - The FBI reported that there were 2,470,462 firearm background checks initiated through the NICS system in September 2022. This compares to 2,518,132 in August 2022 and 2,626,389 checks in September 2021. Companies in the gun space include Sturm, Ruger (RGR), American Outdoor Brands (AOBC), and Vista Outdoor (VSTO). Reference Link

09:42 EDT Sophia Genetics enters multiyear strategic partnership with Microsoft - SOPHiA GENETICS (SOPH) is embarking on a multi-year integrated strategic partnership with Microsoft (MSFT) to improve healthcare workflows globally. This investment in the development of next- generation healthcare will lead the way in enabling multimodal data curation, development, and deployment. As a result, the Microsoft Azure-powered SOPHiA DDM Platform is expected to elevate the standard of care for patients, by delivering advanced outcomes for precision medicine.

09:35 EDT RXO Inc. completes spinoff from XPO - RXO (RXO) began its first day of "regular way" trading on the New York Stock Exchange, officially completing its spinoff as an independent publicly traded company. RXO is the former tech-enabled brokered transportation platform of XPO (XPO). Drew Wilkerson, CEO of RXO, said, "Today is a landmark moment for our business. With the launch of RXO, we've established a standalone tech-enabled pure-play that will continue to thrive in any market. RXO is well-positioned to unlock value for our stakeholders."

09:33 EDT Amazon Music expands offering for Prime members - Amazon Music has expanded its offering for Prime members, "bringing them a full catalog of 100 million songs and the most top podcasts available ad-free, at no additional cost to their membership," the company announced. "With today's news, Prime members can shuffle play any artist, album, or playlist, plus stream a selection of All-Access playlists on demand. Prime members can also access the largest catalog of ad-free top podcasts," Amazon stated. Reference Link

09:29 EDT Lexaria Bioscience receives IRB approbal four human oral nicotine study - Lexaria Bioscience announced that independent review board approval has now been received for human clinical nicotine study NIC-H22-1, and that human dosing will begin soon. Study NIC-H22-1 is a 36-person human pharmacokinetic randomized, double blinded, cross-over study conducted in current cigarette smokers, wherein each person will visit the laboratory to be dosed three times over a period of weeks. During each visit only one oral nicotine pouch will be administered and evaluated: either DehydraTECH-nicotine; On! brand manufactured by Altria; or Zyn brand manufactured by Swedish Match. Predetermined questionnaires for subjective evaluation will be used for each oral nicotine pouch, and blood samples will be taken a total of 8 times per visit to conduct objective evaluations related to quantity of nicotine in blood at various time points, and more. Vital signs such as temperature, blood pressure, heart rate and respiratory rate will also be collected. Subjective evaluations related to throat burn, user experience, gastrointestinal experience and more will be conducted. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands. The study had earlier faced certain time extensions due to manufacturing and logistics, those issues since resolved. The study is fully funded from internal company resources. Lexaria will provide further updates and any relevant material findings in due course from this study as they become available. As reported on October 5, 2021, Lexaria demonstrated in animal study NIC-A21-1 that nicotine oral pouches using DehydraTECH technology were 10x to 20x faster in reaching peak delivery of nicotine to bloodstream than controls

09:26 EDT Merit Medical announces appointment of Wright to Chief Commercial Officer - Merit Medical Systems announced the appointment of Merit's long-time executive, Joe Wright, as Merit's Chief Commercial Officer. In this role, Wright will be responsible for spearheading the company's overall commercial strategy.

09:23 EDT Pieris Pharmaceuticals doses first subject in Phase 1 trial of PRS-220 - Pieris Pharmaceuticals announced that the first subject has been dosed in the phase 1 study of PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis and other forms of fibrotic lung disease. The phase 1 dose escalation study will evaluate the safety, tolerability, and pharmacokinetics of PRS-220 in heathy volunteers.

09:20 EDT Wells Fargo in resolution talks with CFPB regarding number of probes - Wells Fargo said last night in its quarterly regulatory filing: "The Company is in resolution discussions with the CFPB regarding a number of CFPB investigations, inquiries, and other matters, including automobile lending matters, consumer deposit account related matters, and mortgage lending matters. There can be no assurance as to the outcome of these discussions. As previously disclosed, the Company entered into an agreement to resolve investigations by state attorneys general."

09:20 EDT Atossa Therapeutics to acquire stake in privately held DCT - Atossa Therapeutics announces that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, DCT. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. "This investment in DCT is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space," commented Steven Quay, M.D., Ph.D., Atossa's CEO, Chairman and President. "We believe that as an active investor in the development of DCT we will be well positioned to evaluate future opportunities while strategically managing our cash position." Atossa will acquire shares equal to 19.99% of the outstanding capital stock of DCT as of today for a cash payment of $2 million. The transaction is expected to close in the fourth quarter.

09:19 EDT Intermex completes La Nacional acquisition of U.S. based assets - International Money Express, Intermex, has completed its acquisition of Envios de Valores La Nacional. The acquisition of La Nacional strengthens the Company's presence in the Dominican Republic and further establishes Intermex as a market-leading remittance provider with a greater than 20% share in 7 key markets to Latin America. These markets include Mexico, Guatemala, Honduras, El Salvador, Dominican Republic, Nicaragua and Ecuador, and comprise 87% of all US remittances to Latin America. "Acquiring La Nacional represents a significant step forward in our expansion plans," said Bob Lisy, chairman, chief executive officer, and president of Intermex. "This transaction leverages our current strengths and positions our company with market leading share to the Dominican Republic. Intermex is a stronger company today as a result of this acquisition." Intermex paid cash of $42.3M on closing, subject to customary purchase price adjustments, for La Nacional and anticipates up to another possible $2.4M in contingent consideration to be paid in 2023 if La Nacional achieves certain financial and operational targets.

09:17 EDT Vuzix acquires SAP software solution provider Moviynt - Vuzix has acquired Moviynt, a US-based SAP Certified ERP platform software solution provider, to support handheld mobile phones and scanners used in logistics, warehousing and manufacturing applications. With the acquisition, Moviynt becomes a Vuzix wholly owned subsidiary. The acquisition is expected to be accretive with a low six figure revenue contribution projected for 4Q. Moviynt's SAP-based ERP mobility software solution is currently deployed in multiple customer sites and is undergoing proof of concept evaluations at several new warehousing sites across the United States and in Europe at a Fortune 500 aerospace and defense customer. Moviynt, a boutique specialized software firm which was founded in 2018 by three principals, has developed a logistics mobility software platform which eliminates traditional middleware, and is device agnostic.

09:16 EDT Amazon launches merchant cash advance Program provided by Parafin - Amazon launched a new financing solution, a merchant cash advance, provided by Parafin-a U.S.-based provider of growth capital for sellers. This secure financing option ties payment on the cash advance to a portion of sellers' future sales for a fixed capital fee and provides eligible Amazon sellers with easy and quick access to capital when they need it, paired with flexible payment plans. With this program, sellers can access capital in a matter of days with transparent and capped rates, no fixed term, no personal guarantee, no credit checks or excessive paperwork, and no late fees. The program rolls out to some U.S.-based businesses today, and it will be available to hundreds of thousands of eligible sellers by early 2023. This new merchant cash advance, through which eligible businesses can access capital from $500 up to $10M, provides sellers with financing opportunities to expand their businesses, protect margins, develop new products, grow inventory, and efficiently manage cashflow. A flexible payment schedule is determined by a fixed percentage of the seller's Gross Merchandise Sales until the funding is paid off, with no minimum payments, no interest , and no collateral required-unlike a traditional loan. Payments are only required during periods that a seller has made sales, and the fixed payment rate ultimately protects them during periods of slow or no sales. This financing option will provide sellers that have been selling on Amazon.com for at least three months with an additional solution for their financial needs alongside the existing financing solutions portfolio of term loans, interest only loans, and lines of credit provided by Amazon and its third-party financing partners. "Amazon is committed to providing convenient and flexible access to capital for our sellers, regardless of their size," said Tai Koottatep, director and general manager, Amazon WW B2B Payments & Lending. "Today's launch is another milestone in strengthening Amazon's commitment to sellers, and builds on the strong portfolio of financial solutions we already provide. This latest offering significantly expands sellers' reach and capabilities, and broadens their access to capital in a flexible way-one that helps them control their cashflow, and by extension, their entire business."

09:14 EDT DuPont completes M&M divestiture to Celanese - DuPont (DD) completed the previously announced divestiture of the majority of its former Mobility & Materials segment to Celanese (CE) for a purchase price of $11B in cash, subject to customary transaction adjustments in accordance with the transaction agreement dated February 17. The results of the M&M Business were reclassified and reported as discontinued operations beginning in first quarter 2022 for current and historical periods.

09:13 EDT Wish enters partnership with P2C software company Productsup - ContextLogic announced a new partnership with Productsup, a P2C software company. The Wish global online marketplace has selected Productsup's product-to-consumer, P2C platform, a leading commerce solution, to simplify how merchants manage their product data on Wish. As part of this new partnership, Wish merchants will be able to access Productsup's platform via an integration, allowing them to manage and integrate their product catalogs to the Wish marketplace with more ease, accuracy, and speed. Productsup provides businesses with enhanced visibility and control over their product data to ensure they understand consumer expectations and better maximize their sales. "We're a global ecommerce platform, and our merchants typically sell across several marketplaces - which can make maintaining a unified presence a very complex process. For this reason, we're thrilled to have found a P2C management partner in Productsup," said Sarah Luo, VP, Merchant Operations. "At Productsup, we know how hard it is to be a merchant today, as you need to keep up with all of the individual platform requirements and formats for different marketplaces when uploading your product catalog. Together with Wish, we look forward to helping merchants streamline and automate this process," said Saskia Van De Ven, SVP, Global Partner Organization, Productsup. Wish continues to invest in enhancing the merchant experience. Recently, Wish announced a partnership with eDesk - an ecommerce customer support platform aimed to empower Wish merchants with more resources and tools to provide excellent customer support experiences.

09:11 EDT Myriad Genetics acquires Gateway Genomics for $67.5M in cash - Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests including the No. 1 selling SneakPeek Early Gender DNA Test. SneakPeek reveals a baby's gender at six weeks into pregnancy -- the only at-home test to do so with 99% accuracy and the earliest method available. Approximately 3.6 million babies are born in the United States every year2, and SneakPeek attracts over 4 million annual visitors to its website, capturing a large percentage of pregnant families who could benefit from a range of prenatal care options. Through expanded online engagement, consumers who use SneakPeek also can learn the benefits of other forms of genetic testing offered by Myriad Genetics. Over the last three years, SneakPeek has grown at a compound annual rate exceeding 20%. SneakPeek is offered directly to consumers at sneakpeektest.com, online channel partners, and more than 1,850 clinicians in the U.S. and select international markets. The test has strong brand loyalty and a 76-point Net Promoter Score. It is the best-selling prenatal DNA test on Amazon and the top searched gender test on Google with more than 9,000 reviews and a 4.5 star average rating. Myriad Genetics acquired Gateway Genomics for an upfront cash purchase price of $67.5 million, subject to customary working capital adjustments and an escrow of $7.5 million. Gateway has the opportunity to earn up to an additional $32.5 million of cash payments in 2023 and 2024 if certain revenue, volume synergy and EBITDA targets are achieved. Projected revenues for Gateway in calendar year 2022 are approximately $20 million. The core Gateway business is expected to grow over 20% compounded over the next three to five years, excluding synergies, and is expected to be neutral to Myriad's earnings and operating cash flows in 2023. Gateway is also expected to be accretive to Myriad's growth rate, earnings and operating cash flows in 2024.

09:08 EDT Cingulate completes fed/fast study assessing food effect with CTx-1301 - Cingulate announced the completion of its study assessing the effect of food on absorption of its lead candidate CTx-1301, an investigational medication for the treatment of Attention Deficit / Hyperactivity Disorder, ADHD. Results are expected by the end of the year. "As Cingulate proceeds with its mission to bring next-generation medications to patients where standard-of-care treatments result in suboptimal outcomes, we are pleased to have completed this trial advancing our understanding of the absorption and bioavailability of our potentially paradigm-shifting compound for ADHD treatment," said Shane J. Schaffer, Cingulate Chairman & CEO.

09:07 EDT Embark Technology launches coast-to-coast backbone of Embark Coverage Map - Embark Trucks announced the launch of the coast-to-coast backbone of the Embark Coverage Map, preparing key Sunbelt markets to be served by Embark fleet partners. The Coverage Map includes nine transfer point sites in cities across the Sunbelt, including new locations in Dallas, El Paso, Atlanta, and Jacksonville, to accommodate planned autonomous freight volume in key markets and provide anticipated operational support for carriers and shippers using Embark-powered trucks. Embark strategically selected these nine sites to eventually automate crucial shipping lanes for its carrier partners. "Our carrier partners have a meaningful portion of their loads concentrated on a select set of lanes between major markets in the Sunbelt," said Embark CEO Alex Rodrigues. "We are delivering on one of our key 2022 objectives by activating these key markets as one cohesive network today, giving carrier partners the line of sight they need to plan their deployment of Embark-equipped trucks, improving the ecosystem's ability to rapidly scale in 2024."

09:05 EDT AIM ImmunoTech treatment of Ebola Virus Disease granted orphan designation - AIM ImmunoTech's rintatolimod was granted orphan designation from the FDA as a treatment of Ebola Virus Disease, according to a post to the agency's website. Reference Link

09:04 EDT ModivCare appoints L. Heath Sampson as CEO - Modivcare announced that the board of directors has confirmed the appointment of L. Heath Sampson as the company's next president and CEO, effective immediately. The board of directors has also elected Sampson to serve as a member of the board. Sampson has been serving as the company's interim CEO since the departure of his predecessor, and he will continue to serve as the company's CFO until his successor in that capacity is identified.

09:02 EDT Sunrun to build, operate Puerto Rico's first VPP - Sunrun announced it has been exclusively selected by Puerto Rico's electric utility provider to help rebuild and transform the island's energy system through the development of a 17 megawatt virtual power plant, VPP, the first distributed large-scale storage program on the island. Sunrun will spend the next year enrolling customers into the program and begin networked dispatches in 2024. "Puerto Ricans are ready to make the move to reliable independent clean energy solutions that will increase their sense of safety and security in their own homes," said Sunrun CEO Mary Powell. "We're solving energy insecurity on the island by switching the model so that solar energy is generated on rooftops and stored in batteries to power each home, and then shared with neighbors, creating a clean shared energy economy. That way, residents not only have control over their energy at home, but can also share power with their community and be compensated for it."

09:01 EDT Edwards Lifesciences authorizes $750M accelerated share repurchase - Edwards Lifesciences has executed an accelerated share repurchase agreement to repurchase $750M of Edwards' common stock. With this transaction, Edwards has repurchased more than $1.7B of shares in 2022. Under the terms of this ASR, Edwards will receive an initial delivery of approximately 8 million shares and the remainder at the maturity of the ASR. The company is funding the share repurchase under the ASR with its existing cash. Following this repurchase, Edwards has approximately $900M remaining in its share repurchase authorization approved by its Board of Directors.

08:54 EDT Forza X1 begins water testing phase with FX1 electric boat - Forza X1 announced that it launched and sea-trialed its 25-foot electric-powered FX1 catamaran this past Friday. "I'm proud to announce that we have officially begun the water testing phase of our FX1 dual console 100% electric boat," says Jim Leffew, CEO and President of Forza X1, Inc ."From the beginning, the Forza team set out to build electric boats geared towards mass appeal and mass production. From an idea to an Initial Public Offering, to a ceremony with North Carolina Governor Roy Cooper announcing the location of our future manufacturing facility dedicated to building electric motors and electric boats. A lot of intense effort has been put into this vision since the very beginning. And when the test day finally arrived, our engineers, electricians, boat builders, and supporting staff were anxious as a lot was riding on a successful sea trial."

08:53 EDT Media and Games Invest to relocate registered office to Sweden - Media and Games Invest held its Extraordinary General Meeting today on November 01, 2022. Remco Westermann, CEO and Member of the Board of Directors "Sweden will be Media and Games Invest SE's new domicile. At today's EGM all remaining necessary and formal resolutions were passed. Following this final approval by our shareholders, the technical execution of the relocation is planned for January 2023. Together with the expansion of the Board, the implementation of an Audit and a Remuneration Committee as well as the appointment of Deloitte as the Groups new Swedish Auditor, we have taken significant steps on the governance side in line with previous communication. Having grown quite fast, these changes were necessary to further professionalize and to support our future growth path. When we started this process, we did not envision how difficult a change of jurisdictions for a dual listed European company is. So, we are even happier now that the remaining part of the relocation is sheer implementation. Additionally, Deloitte was elected today as our new auditor; I am looking forward to work with them." Results of the Extraordinary General Meeting In accordance with the proposals of the Board of Directors, the Extraordinary General Meeting resolved on the following agenda topics: The following ordinary resolutions, each as described in detail in the notice for the Extraordinary General Meeting as previously published by the Company, were unanimously approved by the votes present: Resolution to adopt principles and instructions for the nomination committee. Approve the appointment of Deloitte Sweden AB as Auditors of the Company for FY 2023, effective from the date the Company's registration as a Swedish company, and to authorize the Board of Directors to fix their remuneration. The following ordinary resolution was approved with 99.97% of the votes present: Resolution on the ESOP. The following extraordinary resolutions, each as described in detail in the notice for the Extraordinary General Meeting as previously published by the Company, were unanimously approved by the votes present: Extraordinary resolution to approve the change in name of the Company from Media and Games Invest SE to MGI - Media and Games Invest SE and, to approve the new Memorandum and Articles of Association of the Company to effect this change. Extraordinary resolution to approve a transfer proposal for the re-domiciliation of the Company from Malta to Sweden and to approve the new statutes of the Company to be adopted following its re-domiciliation and upon registration as a Swedish company. The following extraordinary resolution was approved with 99.54% of the votes present: Extraordinary resolution to authorise the Board of Directors to issue shares, options, warrants and convertibles in the Company. As such all resolutions of the EGM have been approved by the shareholders.

08:52 EDT Andersons purchases Bridge Agri Partners - Andersons has purchased Bridge Agri Partners. Bridge Agri Partners specializes in providing ingredients to the pet food industry. Bridge Agri Partners will continue to work under the Bridge Agri Partners name as a wholly owned subsidiary of The Andersons.

08:50 EDT Olympus Partners to sell Liquibox to Sealed Air, terms not disclosed - Olympus Partners is pleased to announce it has agreed to sell Liquibox to Sealed Air. Liquibox is a manufacturer of sustainable liquid packaging solutions offering a wide assortment of bag-in-box solutions as well as fluid dispensing fitments to a variety of end markets including food and beverage, consumer products, and healthcare. Under Olympus' ownership, Liquibox has experienced significant growth including opening a state-of-the-art greenfield facility in Madrid, Spain. Liquibox employs ~1,300 team members across North America, Europe, Africa, Asia and Australia.

08:49 EDT Greenlane enters strategic agreement with Leaf Trade - Greenlane Holdings announced its strategic agreement with Leaf Trade to feature Greenlane products on its platform. The Leaf Trade agreement is part of the Company's business strategy to capitalize and accelerate growth and profitability by including Greenlane as an ancillary brand on Leaf Trade's business-to-business marketplace and increasing its visibility. The Leaf Trade platform comprehensively streamlines the ordering and fulfillment, payment, and post-sale reporting processes in highly regulated cannabis markets. The technology company partners with some of the largest multi-state operators and serves over 25 markets. By partnering with Leaf Trade, Greenlane will have the tools and technology needed to continue to succeed in the increasingly competitive and highly regulated cannabis market. Greenlane plans to make available on the platform all of its family of brands including Higher Standards, Marley Natural, DaVinci, Groove, and Eyce, as well as partner brand Storz & Bickel and our newest partner brand AUXO.

08:47 EDT Chefs' Warehouse announces acquisition of Chef Middle East - The Chefs' Warehouse announces that it has acquired Chef Middle East, CME, a specialty food distributor with operations in the United Arab Emirates, Qatar and Oman, from Gulf Capital. "This is exciting news for The Chefs' Warehouse, our partners, employees and our new colleagues at Chef Middle East. Similar to our positioning in the US and Canada, CME is the premier provider of specialty food products to the higher-end restaurants, hotels and catering establishments in the region. Their product portfolio mirrors ours in many ways and includes high-quality imported specialty foods, meat and seafood, pastry and bakery goods along with broadline product lines. We thank Gulf Capital for entrusting us to continue the growth of CME into a leading foodservice player." - The Chefs' Warehouse Chairman & CEO, Christopher Pappas.

08:46 EDT Exela Technologies expands contract with consulting firm - Exela Technologies expanded a contract with a major consulting firm to implement Exela's Intelligent Lockers in its new building located in Mexico. With Intelligent Lockers currently set up at the consulting firm's US locations, Exela will install lockers providing the same workplace experience to the Mexico based staff. The uptake for Exela's Digital Mailroom and Intelligent Locker solutions have been a significant value add for the firm in the US.

08:44 EDT Meta Materials partners with DuPont Teijin Films, Mitsubishi Electric Europe - Meta Materials announced it has entered into a Memorandum of Understanding in partnership with DuPont Teijin Films and Mitsubishi Electric Europe. Using META's PLASMAfusion, the parties plan to scale a proprietary, high volume, roll-to-roll manufacturing system for film-based, coated copper current collectors. The film-based products will reduce battery weight and cost, improve energy efficiency, extend vehicle range, and enhance safety against the risk of battery fires compared to standard Li-Ion batteries for electric vehicles and other use cases. The MOU is focused on developing battery materials, such as coated copper current collectors and solid-state battery electrodes, as a multi-year project in several stages: a pilot-scale roll-to-roll system, to be followed by an industrial scale mass production line, and further development of the application to the production of solid-state batteries. META will contribute the PLASMAfusion technology platform, system development and independent testing of finished cells; DuPont Teijin Films will develop and supply the polyester substrates, and Mitsubishi Electric Europe will contribute automation technology, expertise, and interface to machine builders.

08:41 EDT SurgePays appoints Jeremy Gies as president, SurgePays Fintech - SurgePays has appointed Jeremy Gies, a senior sales, business development and operations executive, as President of the Company's subsidiary, SurgePays Fintech, Inc. Gies has more than 25 years' experience in supporting businesses in the telecom, fintech and prepaid channels. He will be responsible for developing and expanding our nationwide network of convenience stores channel with the primary focus on adding stores transacting on the SurgePays network while increasing sales per store.

08:40 EDT Navitas Semiconductor delivers keynote at IEEE Power Semiconductor Workshop - Navitas Semiconductor announced that Dan Kinzer, the company's co-founder and COO/CTO, will present a keynote speech on next-generation semiconductor technology at the forthcoming IEEE WiPDA workshop. Taking place from November 7th-9th 2022, the ninth WiPDA Workshop provides a forum for device scientists, circuit designers and application engineers from the Power Electronics & Electron Devices Societies to share wide bandgap technology updates, research findings, experience and potential applications. Mr. Kinzer's keynote "High-speed GaN and SiC: $22B of pure-play power semiconductors" spotlights key market drivers and technology developments in GaN and SiC as they continue to displace legacy silicon in a growing range of applications including mobile ultra-fast chargers, data centers, renewables and EVs. An additional technical paper, "Advancement in Integration for GaN Power ICs: Autonomous Protection and Loss-Less Sensing", will be presented by Tom Ribarich, Navitas' Sr. Director Strategic Marketing.

08:39 EDT SciSparc signs agreement with logistics facilities in New Jersey - SciSparc announced that SciSparc Nutraceuticals, its wholly owned subsidiary, has signed an agreement with logistics facilities in New Jersey, U.S. as part of SciSparc Nutraceuticals' plans to expand sales of its Wellution products to new online platforms. "The success of an online brand depends, amongst other things, on operational efficiency and low costs that enable high margins on each sale. The establishment of access to advanced logistics infrastructure, to support our shift from selling our products on Amazon to making direct sales and expanding to additional eCommerce platform, is a key element in our plans for the future," Oz Adler, SciSparc's Chief Executive Officer, commented. "The facilities we engaged with offer a wide range of services - from intake and storage space for WellutionTM products, order processing direct shipping to the brand's customers and more. We intend to commence preparations for the launch of our direct sales operations and we explore possible platforms to launch in the brand's products".

08:38 EDT Safe-T privacy platforms reach over 5M downloads - Safe-T Group announced that its privacy application reached over 5,000,000 downloads in aggregate by Android, Apple iOS and Windows personal computers users. "We are delighted that our customer acquisition program is performing well and continues to yield. During the last six months we significantly increased our exposure to a wide range of users' base by launching our privacy solution in all leading application platforms, which enables us to deliver continued volume growth. In addition, we secured funding to support our future plans for the growth of our business and we are happy that our customers are validating our strategy every day," commented Shachar Daniel, Chief Executive Officer of Safe-T.

08:37 EDT Processa Pharmaceuticals identifies NGC dosage regimens for Phase 2B trial - Processa Pharmaceuticals announces positive results from its ongoing Next Generation Capecitabine, NGC, Phase 1B trial. The data collected has allowed Processa to estimate the timeline of dihydropyrimidine dehydrogenase, DPD, irreversible inhibition and the formation of new DPD after PCS6422 administration. NGC regimens were also identified that are safe with different systemic and tumor exposure profiles to 5-FU. During the first 24 to 72 hours after administration of PCS6422 in the Phase 1B trial, less than 10% of the 5-FU was converted into the metabolites that only cause side effects, significantly less than the 80% reported for FDA-approved capecitabine. The potency of NGC was approximately 50-times greater than the potency of FDA-approved capecitabine. In addition, the half-life of 5-FU after the initial administration of PCS6422 and capecitabine was found to be significantly greater at 2 to 6 hours versus the typical 5-FU half-life of approximately 45 minutes after capecitabine administration. Dr. David Young, President and CEO of Processa, stated, "We have identified NGC regimens that have potency significantly greater than existing therapy and no dose-limiting side effects, unlike existing capecitabine therapy where approximately 25- 60% of the patients require dose modifications or discontinuation. In addition, we understand the effect of different NGC regimens on the timeline of DPD irreversible inhibition and a patient's production of new DPD, allowing us to better define the relationship between various NGC dosage regimens, 5-FU exposure, and the safety of NGC."

08:36 EDT GATX names James Ream as independent chair of board - GATX announced that James Ream has been named as the company's independent chair of its board of directors, effective immediately. Ream succeeds Brian Kenney, who retired as the company's president and chief executive officer in April and who has served on the board as non-executive chair for a transitional period ending October 31. The board previously announced its intention to separate the board chair and CEO roles following the transitional period. Ream has served as GATX's independent lead director for the past five years.

08:35 EDT Eterna enters research collaboration with Michael Andreeff - Eterna Therapeutics announced it has entered into a sponsored research agreement with Michael Andreeff, M.D., Ph.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center. Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna's gene-edited induced pluripotent stem cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immunity, and to promote multilineage differentiation and hematopoietic regeneration in vivo. The Company anticipates that this work will accelerate the development of these therapeutic candidates for the treatment of various diseases including acute myeloid leukemia and solid tumors. Dr. Andreeff is a member of Eterna's Scientific Advisory Board.

08:33 EDT Sabre's SabreSonic Passenger Service System selected by Oman Air - Sabre and Oman Air, the national carrier of the Sultanate of Oman, announced a renewed long-term agreement to help the airline reach its strategic goals. The agreement includes a multi-year renewal of Oman Air's SabreSonic Passenger Service System and a further multi-year extension of its global distribution system agreement. By renewing its exclusive PSS agreement and investing in Sabre's Digital Connect APIs, Oman Air aims to advance its digital retailing strategy, drive revenue growth and increase self-service capabilities. Oman Air will join the Oneworld Alliance by 2024.

08:32 EDT IntercontinentalExchange receives approval for expansion in Canada - Intercontinental Exchange announced it has received approval to operate its ICE TMC fixed income trading platform in all Canadian jurisdictions, paving the way for full access to ICE's leading electronic municipal bond marketplace. ICE TMC, which is part of ICE Bonds, provides market participants with access to an all-to-all market for trading municipal, corporate, agency and government bonds, as well as Certificates of Deposit. ICE's municipal bond offering brings together ICE's industry-leading Continuous Evaluated Pricing for munis, pre-trade analytics and access to the full breadth of ICE's municipal bond market liquidity, which includes depth of market from both ICE TMC and ICE BondPoint, which received approval to operate in Canada on June 19, 2020. "Canada has vibrant fixed income trading and investment communities that understand our products and can benefit from access to our fixed income liquidity," said Peter Borstelmann, President of ICE Bonds. "We pride ourselves on working closely with our customers. As we expand our network to include Canadian accounts, we look forward to providing the data, analytics and trading tools they need to gain greater transparency into markets and manage risk."

08:30 EDT electroCore announces distribution agreement with Joerns Healthcare - electroCore announced today that gammaCore Sapphire, the first and only FDA-cleared, non-invasive device to treat and prevent multiple types of headache pain via the vagus nerve, will be distributed and billed exclusively by Joerns Healthcare within selected managed care health systems. "We are excited to be working with Joerns as we expand patient access to our therapy," commented Dan Goldberger, Chief Executive Officer of electroCore. "Joerns is a trusted partner of many large managed care companies, and this partnership enables us to expand the use of gammaCore nVNS technology for sufferers of primary headache within a self-insured managed care organization, reinforcing the company's strategy of providing patients with greater access and ease to our nVNS therapy."

08:28 EDT Missfresh regains compliance with Nasdaq minimum bid price rule - Missfresh Limited announced that it has received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market dated October 31, 2022, informing the Company that it has regained compliance with the Nasdaq Listing Rule 5450(a)(1). As previously announced, Missfresh received a notification letter from the Nasdaq dated June 2, 2022 indicating that the closing bid price for the Company's American depositary shares was below the minimum bid price of $1.00 required for continued listing under the Nasdaq Listing Rule 5450(a)(1) for 30 consecutive business days. According to the Deficiency Notice, if at any time during the 180-day compliance period, the closing bid price of the Company's ADSs is at least $1.00 for a minimum of ten consecutive business days, the Nasdaq will provide the Company written confirmation of compliance and the matter will be closed. According to the Compliance Notice, the closing bid price of the Company's ADSs has been at $1.00 per ADS or greater for 10 consecutive business days from October 17 to October 28, 2022, and the Company has regained compliance with the Minimum Bid Price Requirement and the matter is closed.

08:26 EDT Micron ships qualification samples of 1-beta DRAM technology - Micron Technology announced that it is shipping qualification samples of its 1beta DRAM technology to select smartphone manufacturers and chipset partners and has achieved mass production readiness with the world's most advanced DRAM technology node. The company is debuting its next generation of process technology on its low-power double data rate mobile memory, delivering top speed grades of 8.5 gigabits per second. The node delivers significant gains across performance, bit density and power efficiency that will have sweeping market benefits. Beyond mobile, 1beta delivers the low-latency, low-power, high-performance DRAM that is essential to support highly responsive applications, real-time services, personalization and contextualization of experiences, from intelligent vehicles to data centers.

08:24 EDT Vyant Bio announces one-for-five reverse stock split - Vyant Bio announced that the Company will effect a 1-for-5 reverse stock split of its outstanding common stock. This will become effective for trading purposes as of the commencement of trading on Wednesday, November 2, 2022. Vyant Bio's common stock will continue to trade on The Nasdaq Capital Market under the symbol "VYNT" and under a new CUSIP number, 92942V208. The reverse stock split is intended to increase the per share trading price of Vyant Bio's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

08:23 EDT Adams Resources repurchases all outstanding KSA shares, signs new loan agreement - Adams Resources announced the repurchase of all of the shares of Adams common stock owned by KSA Industries, the company's largest stockholder, and members of the family of the late Kenneth Stanley Adams, Jr., the company's founder, who are affiliated with KSA. The total purchase price was approximately $70M for 1,942,433 shares, or $36 per share. This represents approximately 44.2% of the total shares outstanding, reflecting an effective control position. The $36 share price represents approximately a 10% premium over the year-to-date weighted average daily closing share price as of October 28th, 2022. Following the transaction, the company will have 2,452,404 shares of common stock outstanding. The purchase will be funded by a combination of existing cash on hand and a new term loan. Additionally, the company has entered into a new five-year $85M credit agreement led by Cadence Bank. This new agreement replaces the company's existing three-year $60M facility and includes a $25M term loan which amortizes over 10 years, with a balloon payment after 5 years and $60M in revolving credit capacity. The new agreement includes letter of credit capacity of $30M, or $10M greater than the previous agreement.

08:21 EDT Phathom Pharmaceuticals announces placement of $40M in capital - Phathom Pharmaceuticals announced that up to an additional $40 million in non-dilutive capital has been secured from an additional investor under the terms of Phathom's revenue interest financing agreement announced on May 4, 2022. Up to $40 million has been committed, comprised of $15 million upon FDA approval of vonoprazan for treatment of EE, and $25 million upon achievement of a sales milestone. This additional potential funding is subject to the revenue interest financing agreement with Sagard Healthcare Partners, NovaQuest Capital Management, and Hercules Capital, Inc. (HTGC) which provided Phathom with the option to add additional investors for up to $40 million in additional funding. This additional $40 million in potential funding increases the total financing available to Phathom under the agreement to up to $300 million. In exchange for the commitment to provide these cash payments, the investors will receive a 10% royalty on Phathom's net sales of products containing vonoprazan. The royalty payment will be reduced to 1% on incremental net sales that exceed certain annual thresholds following regulatory approval of vonoprazan for symptomatic non-erosive reflux disease. The total royalties payable by Phathom to the investors are capped at 2.0x of the total payments received from the investors. Upon achievement of the cap amount, the agreement will terminate.

08:20 EDT Rhythm Pharmaceuticals announces setmelanotide granted BTD from FDA - Rhythm Pharmaceuticals announced that setmelanotide received Breakthrough Therapy Designation, BTD, from the U.S. Food and Drug Administration, FDA, for the treatment of hypothalamic obesity. "Breakthrough Therapy Designation marks a meaningful step in our effort to advance setmelanotide as quickly as possible for hypothalamic obesity, reflecting both the strength of our interim Phase 2 data and the significant need for a novel therapy that can transform the care of patients living with this rare, acquired obesity," said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm. "We look forward to initiating a Phase 3 trial evaluating setmelanotide in hypothalamic obesity in early 2023." Breakthrough Therapy Designation was granted based on results from a Phase 2, 16-week clinical study of setmelanotide. Rhythm announced positive interim results from this trial in July 2022, with preliminary data showing that all 11 evaluable patients achieved a BMI decrease of more than 5 percent, with a mean reduction in BMI of 17.2%, at 16 weeks on setmelanotide therapy.

08:19 EDT Lumen wins $1.5B Defense Information Systems Network contract - Lumen has won a $1.5B contract from the Defense Information Systems Agency to provide essential network transport and communications services in the U.S. Indo-Pacific Command Area of Responsibility. Lumen will supply the Defense Information Systems Network with high capacity, end-to-end communications services that enable the U.S. Department of Defense to achieve U.S. national security objectives in the 36-nation Asia Pacific region. The indefinite-delivery/indefinite-quantity contract has a $1.5B ceiling over its 10-year period of performance and represents new business for Lumen.

08:19 EDT Acumen publishes Phase 1 trial design, clinical development plan for ACU193 - Acumen Pharmaceuticals announced that it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers. The article was published in the Journal of Prevention of Alzheimer's Disease and outlines the design of its ongoing Phase 1 INTERCEPT-AD trial for ACU193 and planned criteria for advancing to a Phase 2/3 clinical trial based on recent advancements in clinical research on Alzheimer's disease. The criteria for advancing from the Phase 1 to a Phase 2/3 trial will be based on safety and tolerability, pharmacokinetic parameters, and target engagement at doses that have acceptable safety and tolerability. The Phase 2/3 trial would initiate with a patient sample size typical of a Phase 2 trial but would include an interim analysis to determine whether to increase the sample size to meet the statistical power of a typical Phase 3 trial. This interim analysis may be based on several cognitive measures and various biomarkers, including phosphorylated tau in the blood and cerebrospinal fluid. "Recent clinical results in the Alzheimer's disease field are consistent with the concept that targeting Abeta species other than monomers or amyloid plaques may lead to more effective or safer disease-modifying treatments that the field has long needed," said Eric Siemers, M.D., Chief Medical Officer at Acumen Pharmaceuticals and first author on the publication. "The Phase 1 trial design and clinical development plan for ACU193 reflect several advances in Alzheimer's disease research methodology and incorporate moving from a first-in-humans trial directly to a registration-quality Phase 2/3 trial which uses an adaptive design. Considerable evidence is available supporting oligomers as a promising therapeutic target for Alzheimer's disease, and we are in a position to more rapidly evaluate this target and accelerate the development of a new treatment for patients."

08:18 EDT Charles River and DirectBooks team to streamline primary issuance - Charles River Development, a State Street Company announced a collaboration with DirectBooks enabling investment firms to manage primary issuance workflows in the Charles River Investment Solution or Charles River IMS. DirectBooks optimizes primary issuance of fixed income securities by streamlining communications workflows between underwriters and institutional investors. Currently, 25 underwriters and over 250 institutional investors, including 17 of the top 20 global asset managers by AUM, are live on the platform . Charles River IMS is a front office solution for investment managers and asset owners, including portfolio and risk analytics, order and execution management, full trade lifecycle compliance and an Investment Book of Record. Recently, Lord Abbett & Company, a mutual client of Charles River and DirectBooks, adopted the combined offering to manage primary issuance across their institutional and private client portfolios. "As a leading global fixed income manager, our teams require the latest and most accurate new issuance information," said Nickolas Prala, Trader, Fixed Income Investments at Lord Abbett. "The combination of Charles River's IMS capabilities and DirectBooks' comprehensive structured data will allow us to best serve our clients by making the most prudent and efficient investment decisions."

08:18 EDT MainStreet Bancshares increases dividend 100% to 10c per share - MainStreet Bancshares declared a cash dividend of 10c per common share for Q3, to be paid on November 10 to shareholders of record as of November 4. This is an increase from a cash dividend of 5c per common share in Q2. MainStreet Bank had total assets of $1.9B and total deposits of $1.6B as of September 30.

08:17 EDT Anika Therapeutics reaches primary endpoint in Phase III study of Cingal - Anika Therapeutics announced that Cingal met its primary endpoint in a Phase III Study, demonstrating superiority over triamcinolone hexacetonide steroid alone at 26 weeks post-treatment. The Cingal 19-01 Phase III study is the third completed Phase III study of Cingal and, together with previous studies, has now demonstrated superiority over each of its active ingredients and placebo. Across the three completed Phase III studies, Cingal demonstrated a mean 71% pain improvement from baseline and a mean 91% of Cingal subjects were deemed to be Responders. Anika will engage with the U.S. Food and Drug Administration in the coming months on next steps for U.S. regulatory approval. In parallel, Anika is exploring the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets. "We are excited that Cingal successfully met the primary endpoint of this third Phase III study, and again confirmed the strong and durable pain relief observed in previous studies," said Anika's President and CEO, Cheryl R. Blanchard, Ph.D. "The successful results of this study represent a significant clinical milestone for Anika, and we look forward to meeting with the FDA to discuss next steps for U.S. regulatory approval. We believe that Cingal offers compelling clinical benefits to patients in terms of pain relief, durability of pain relief, responder rates and safety profile based on our established, real-world success with Cingal in over 35 countries outside the United States, as well as the totality of the data observed in our three completed Phase III studies. Cingal is a game-changing, next generation product for patients suffering from osteoarthritis, and we believe these clinical data position us well to further advance Cingal."

08:15 EDT NV5 Global awarded over $60M LNG utility upgrade - NV5 Global announced that it has been awarded a contract valued at over $60M by a prominent Eastern US utility to provide engineering, procurement, and installation of a liquefied natural gas, LNG, facility upgrade. The project involves the replacement and upgrade of existing LNG process systems to improve the safety, reliability, and overall capabilities of the facility. The three-year project is expected to be completed in 2025, and engineering design of the new process systems is underway. The renovation will also increase the system's liquefication capacity to assist in natural gas storage and availability during times of peak demand. "The investments being made by our domestic natural gas utility clients demonstrates their continued commitment to providing efficient and reliable supply of natural gas to their customers," said Dickerson Wright, PE, Chairman and CEO of NV5. "As a leading designer of liquefication systems for utilities, NV5 is well-positioned to support the growing demand for new and retrofitted LNG systems."

08:13 EDT Greenlane announces strategic pact with Leaf Trade to increase B2B vsibility - Greenlane Holdings announced its strategic agreement with Leaf Trade to feature Greenlane products on its platform.The Leaf Trade agreement is part of the Company's business strategy to capitalize and accelerate growth and profitability by including Greenlane as an ancillary brand on Leaf Trade's business-to-business marketplace and increasing its visibility. The Leaf Trade platform comprehensively streamlines the ordering and fulfillment, payment, and post-sale reporting processes in highly regulated cannabis markets. The technology company partners with some of the largest multi-state operators and serves over 25 markets. By partnering with Leaf Trade, Greenlane will have the tools and technology needed to continue to succeed in the increasingly competitive and highly regulated cannabis market. Greenlane plans to make available on the platform all of its family of brands including Higher Standards, Marley Natural, DaVinci, Groove, and Eyce, as well as partner brand Storz & Bickel and our newest partner brand AUXO.

08:12 EDT Urban-Gro closes asset acquisition of DVO Engineering - urban-gro announced the successful completion of its subsidiary urban-gro Engineering's acquisition of substantially all of the assets of Dawson Van Orden effective November 1, 2022. Bradley Nattrass, Chairman and CEO of urban-gro, commented, "DVO provides several levers for growth, including cross-selling benefits, enhanced margin capture, and an expansion of our professional services offering. The added engineering depth is particularly valuable at a time when we are seeing strong demand for both our professional services, and our turnkey design-build offering. We look forward to DVO's contributions as we work together to expand our CEA footprint." urban-gro paid a final purchase price of $6.1M after working capital adjustments, excluding $1.1M of contingent consideration that may become payable in cash or equity at Company's discretion, through a combination of $1.2M in cash, $3.8M of a seller's note paid out over four quarters, and $1.1M of UGRO common stock at a pre-set price of $4 per share, equivalent to 271,875 shares. DVO generated approximately $5.5 million of revenue and greater than 20% EBITDA margins in the trailing twelve-month period ended September 30, 2022.

08:10 EDT Bed Bath & Beyond's buybuy BABY launches first exclusive brand - Bed Bath & Beyond's buybuy BABY banner, a baby and toddler specialty retailer, has launched its first exclusive brand. The mighty goods brand brings customers an exclusive collection of baby and toddler essentials informed by and designed for the realities of parenting which combine designed pieces with prices starting at $2 on apparel, bed and bath products, room decor, nursery furniture, and more. mighty goods products are available exclusively at buybuy BABY stores and online at buybuyBABY.com.

08:10 EDT BigCommerce teams with Snap to broaden customer reach, tap new revenue streams - BigCommerce (BIGC) announced in partnership with Snap (SNAP), the launch of Snapchat for BigCommerce. BigCommerce merchants of all sizes in the US can now directly integrate their store as a one-stop shop to sync product catalogs and create immersive Snapchat ad campaigns to broaden customer reach, open new revenue streams and ultimately scale their business to the next level. Giving merchants access to Snapchat's unique audience of 363 million daily active users opens up incredible opportunities for them to tap into a younger generation of influencers that master impacting a consumer's purchasing decision," said Sharon Gee, vice president of revenue growth and general manager of omnichannel at BigCommerce. "For BigCommerce, Snap's partnership broadens our direct integrations portfolio for omnichannel merchants on the BigCommerce platform, providing access to top performing social, search and marketplace channels from a single platform to sell more and increase revenue. Furthermore, this partnership provides unique benefits to our ecosystem of Omnichannel Certified Partners for merchants on any ecommerce platform via Feedonomics to drive return ad on spend and improve performance on hundreds of growth channels."

08:06 EDT Kiniksa expects cash to fund operations into at least 2025 - Kiniksa continues to expect ARCALYST net revenue for the full-year 2022 of between $115 million and $130 million. Kiniksa expects that its cash and cash equivalents will fund its current operating plan into at least 2025.

08:06 EDT XPeng obtains autonomous driving test for G9 - XPeng announced that it has successfully obtained the Guangzhou Intelligent Connected Vehicle Road Test Permit, making XPENG G9 the first unmodified commercial vehicle to qualify for autonomous driving tests on designated public roads in China.

08:05 EDT McCormick Chief Human Relations Officer Lisa Manzone retiring - McCormick announced that Lisa Manzone, Senior VP, Human Relations, will retire effective December 31. Manzone has been the Chief Human Relations Officer for McCormick and serves on the company's Management Committee, its highest leadership team, for the past seven years. Manzone is currently serving as the Secretary of the Compensation and Human Capital Committee of McCormick's Board of Directors.

07:58 EDT Computer Modelling Group appoints John Mortimer as CTO - Computer Modelling Group is pleased to announce the appointment of John Mortimer as Chief Technology Officer effective November 1, 2022. Mortimer joins CMG from Benevity where he held the role of Vice President, Engineering and was responsible for developing and scaling the enterprise SaaS platform for the organization that is currently used by over 700 of the world's Fortune 1000 companies. In his new role at CMG, he will report directly to CEO Pramod Jain.

07:53 EDT SNDL acquires Zenabis Business - SNDL announced that, in the context of proceedings pursuant to the Zenabis Group's filing under the companies' Creditors Arrangement Act, it has successfully closed its acquisition of the Zenabis Business, pursuant to an approval order of the Quebec Superior Court. The Zenabis Business' core asset is the 380,000-square-foot indoor growing facility in Atholville, New Brunswick, which has an annual production capacity of approximately 46,000 kilograms of dried cannabis and 15,000 kilograms of extraction capacity. The facility previously received EU GMP certification and has exported cannabis shipments to Malta, Israel and Australia. SNDL completed its first international shipment of dried cannabis flower in August of 2022. The company acquired more than 22 million grams of cannabis inventory, which will reduce near-term cultivation requirements and is expected to be monetized through wholesale transactions, international export, and branded product sales, partially through SNDL's network of 185 retail stores. The Zenabis Business' non-core assets include a 255,000-square-foot industrial facility in Stellarton, Nova Scotia, which is under non-binding discussions for sale by SNDL. Certain intellectual property rights for the Zenabis brands and cannabis strains were also acquired.

07:49 EDT Field Trip Health to announce number of new initiatives in coming weeks - Field Trip Health & Wellness released a letter to shareholders from the Company's Chairman & CEO, Ronan Levy, and President, Mujeeb Jafferi. The letter read in part, " We would like to take this opportunity to provide an update on the direction of our business, as we recognize that the rate of change with the psychedelics industry and with Field Trip is exciting and rapid and often hard to keep pace with...In August, FTRP completed a spinout by plan of arrangement, whereby FTRP shares were exchanged for shares in two entities: FTHW, which acquired the globally-recognized Field Trip brand, the 12 Field Trip Health locations and the digital technologies business with Mujeeb and I taking over day-to-day executive management of FTHW; and Reunion Neuroscience (REUN), which continued the drug development efforts with Isoprocin Gluturate and the other pipeline projects. Joseph del Moral stepped in as CEO of REUN, which has since brought on Greg Mayes into the role of CEO while Joseph became Chairman. The ratio for the share exchange was 1 REUN share and approximately 0.86 FTHW shares for each FTRP share held. As the last step in the arrangement, REUN shares were consolidated on a 5:1 basis. Translating the above into what you will see in your brokerage accounts, this means that if you were holding, for example, 1,000 FTRP shares, you would be eligible to receive 1,000 REUN shares and 860 FTHW shares. However, because REUN also completed a 5:1 share consolidation, if you held 1,000 FTRP shares, your holdings post-spinout would be 200 REUN shares and 860 FTHW shares. If you are a registered Field Trip shareholder who holds shares directly in your name with Field Trip's transfer agent, we encourage you to complete and return the letter of transmittal that you received in the mail to Computershare Investor Services Inc., acting as the depositary, in order to exchange your FTRP shares for FTHW and REUN shares. The LOT contains other procedural information related to the spin out, and should be reviewed carefully. For security reasons, we cannot process the LOT for you or send it on to Computershare. .. Since the completion of the spinout, we have been working diligently to chart an even more extraordinary course for the company. On the first day of trading, the assets of FTHW included a globally-recognized brand, 12 leading centres for psychedelic therapies, one of the most seasoned and experienced clinical teams in psychedelics, a digital platform that has organically grown to over 80,000 installs in just about two years and a state-of-the-art research and cultivation facility for psilocybin-production at the University of West Indies. Up to this point, our mission was to prove that psychedelics could be safely, effectively and efficiently delivered and that the world was ready to re-embrace the potential of psychedelics. Now, our focus is scale...Since we started in 2019, 0ver a million people have turned to us for psychedelic therapies or tools and information on psychedelics. Field Trip owns a disproportionately large share of voice in the industry - approximately 40% of media mentions on psychedelics are about or include Field Trip. We believe that trend will only continue to accelerate. So we recently announced that our app, formerly known as Trip, was being rebranded as Field Trip and will play a much more central role in our growth strategy with an accelerated development timeline. We also added a number of new features, music and meditations. In the coming weeks and months, we plan to announce a number of new initiatives, programs and tools that it expects will greatly expand access to, and education around the use of, legal psychedelic compounds and non-ordinary states of consciousness, meaning that more people will be able to access our clinicians and our tools for their mental health and well being. Further, the regulatory landscape continues to shift positively. In the coming weeks, it is expected that voters in Colorado will approve The Natural Medicines Health Act that will, once implemented, enable state-legal access to a variety of psychedelic therapies. The State of Oregon will begin implementing its psilocybin services in early 2023. Recently, the Province of Alberta announced intentions to make psychedelic therapies using most of the classic psychedelics such as psilocybin, LSD, MDMA, DMT and Mescaline available to Albertans. And recently, reports indicate that the White House has commissioned a Task Force to help implement the forthcoming FDA approval for MDMA and other psychedelic-assisted therapies. We believe we are truly just at the beginning of this psychedelic renaissance and we are building Field Trip to not only participate in the coming wave of interest, but to thrive."

07:43 EDT Stealth Biotherapeutics' ALS candidate shows Phase 1 safety and efficacy - Stealth BioTherapeutics announced "encouraging" Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and function. Positive preclinical data demonstrating that treatment with SBT-272 provided neuroprotection of upper motor neurons harboring ALS pathology will be presented at the Northeast Amyotrophic Lateral Sclerosis conference in Clearwater, FL. The company recently received Orphan Drug Designation from the FDA for SBT-272 for the treatment of patients with ALS. Interim results from the Phase 1 study for SBT-272 demonstrated that selected doses are anticipated to result in therapeutic concentrations in the brain based on observed drug levels achieved in preclinical studies. While final safety analyses are ongoing, dose levels identified for subsequent clinical evaluation appear generally safe and well tolerated. These data support further clinical development of SBT-272.

07:41 EDT Ayr Wellness announces new retail locations - Ayr Wellness announces the opening of two new retail stores in Florida, located in Daytona Beach and Lake Worth, as well as the expansion of LEVIA water-soluble cannabis tinctures to its Florida retail menus. "We are excited to see the results from the progress we've made in Florida since acquiring Liberty Health Sciences in 2021. We've opened more than 20 new locations, with our store count now at 52, and have introduced several brands from our national portfolio to the market," said Jonathan Sandelman, Founder and CEO of Ayr. "On our mission to produce the highest quality cannabis at scale, Florida has been instrumental in bringing that vision to life."

07:38 EDT nCino chosen by Peoples Bank to enhance homebuying experience - SimpleNexus announced that Peoples Bank has completed the company-wide rollout of Nexus Engagement and Nexus Origination to offer customers a modern homebuying experience from their phones. Leveraging SimpleNexus' native integrations with the bank's mortgage loan origination system and document provider has allowed Peoples Bank to streamline its document workflow by prompting borrowers to eSign standard disclosures and specialty documents alike. "The forward-thinking leaders at Peoples Bank understand the importance of technology and the central role it plays in consumers' lives," said Ben Miller, CEO of SimpleNexus. "It is an honor to support a bank that, like SimpleNexus, pursues innovation and is passionate about providing excellent service to homebuyers."

07:36 EDT Pennant acquires Kenosha Visiting Nurse Association, a home health provider - The Pennant Group announced that it has acquired the assets of Kenosha Visiting Nurse Association, which provides home health, private duty, and community health services in Kenosha, Wisconsin. "We are pleased to expand our home health operations deeper into southern Wisconsin," said Brent Guerisoli, Chief Executive Officer of Pennant. "KVNA will be a great partner to our senior living affiliates in the area as we further expand the continuum of care and provide life-changing service to the residents of Kenosha and its surrounding communities," Guerisoli added. Guerisoli reaffirmed that Pennant continues to pursue opportunities to acquire home health, hospice and senior living businesses throughout the United States.

07:35 EDT Sage Therapeutics appoints Laura Gault, M.D. as Chief Medical Officer - Sage Therapeutics announced the appointment of Laura Gault, MD, Ph.D. as Chief Medical Officer. In her new role, Dr. Gault will focus on advancing Sage's current and emerging product pipeline through all stages of development.Dr. Gault brings more than 15 years of pharmaceutical industry experience advancing programs at early and late stages of development in rare and common diseases. She has led multidisciplinary teams focusing in neuropsychiatry, neuroinflammation and neurodegeneration and has extensive knowledge of clinical trial design and conduct, and the regulatory landscape in these areas. In her previous role, Dr. Gault was Vice President, Therapeutic Area Head for Neurology and Ophthalmology at Alexion/Astra Zeneca Rare Disease and was responsible for the development of ravulizumab in generalized myasthenia gravis and neuromyelitis optica spectrum disorder and the initiation of new programs in dermatomyositis, Guillain-Barre syndrome, geographic atrophy and gMG. Prior to that, she held positions as Vice President, Neurology Clinic Development at Vertex Pharmaceuticals and Group Project Leader at AbbVie.

07:35 EDT Monte Rosa announces first patient dosed in phase 1/2 trial of MRT-2359 - Monte Rosa Therapeutics announced the company has dosed the first patient in its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer. "MYC transcription factors are well-defined drivers of human cancers, and disrupting protein translation has emerged as a promising path to address this highly prevalent disease pathway. Dosing the first patient is a significant milestone in developing MRT-2359 as a therapeutic option for MYC-driven cancers," said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa. "We have designed our Phase 1 trial to move efficiently through dose escalation and, by focusing on tumor types where MYC expression is prevalent, to improve our chances of seeing early signals of clinical activity. We are encouraged by the strong preclinical data and hope that MRT-2359 will make a meaningful difference in the lives of patients."

07:33 EDT Irwin Naturals CFO Philippe Faraut resigns - Irwin Naturals announced that Philippe Faraut has tendered his resignation as CFO, Secretary, and Board Member of the Company, effective November 1, 2022. Sean Sands, the company's current Vice President of Finance, will be promoted to fill the roles of CFO and Secretary for Company.

07:31 EDT Harmony Biosciences reports topline Phase 2 results of pitolisant - Harmony Biosciences announced initial topline results from its Phase 2 proof-of-concept study in patients with Prader-Willi syndrome - PWS -, which showed a positive signal on improvement in the primary outcome related to excessive daytime sleepiness - EDS -. The Phase 2 clinical trial was designed to assess the safety and efficacy of pitolisant in patients with PWS. The primary endpoint of this study was the evaluation of EDS as measured by change from baseline to end of treatment on the Epworth Sleepiness Scale for Children and Adolescents Parent/Caregiver Version. Mean change from baseline to EOT on the ESS-CHAD Parent/Caregiver Version scores ranged from -3.7 to -5.5 across all age groups and treatment groups, representing a clinically meaningful change. In two of the three age groups - children and adults -, there was a clinically meaningful difference between pitolisant and placebo, driven by the high dose pitolisant treatment group. In the adolescent age group, there was a high placebo response of a magnitude three times that seen in the other two age groups, which resulted in no clinically meaningful difference between pitolisant and placebo in this age group. Overall safety/tolerability profile was consistent with the known safety/tolerability profile of pitolisant. Adverse events were reported in 57% of patients on pitolisant and 65% of patients on placebo. These results represent the initial topline data with the full data set expected before the end of the year. The full results will be presented at a future medical meeting and submitted for publication in a scientific journal.

07:30 EDT ADC Therapeutics appoints Kristen Harrington-Smith as chief commercial officer - ADC Therapeutics (ADCT) announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17. The company also announced the appointment of Peter Graham as chief legal officer, effective November 1. Both Harrington-Smith and Graham will serve on the company's leadership team. Smith has over 20 years of experience in the pharmaceutical industry. Most recently, she has served as chief commercial officer of Immunogen (IMGN).

07:27 EDT LCI Industries CFO Brian Hall to resign - LCI Industries announced that Brian Hall, LCI Industries' executive VP and CFO, has notified the company of his intention to resign from the company to pursue philanthropic ventures and opportunities as well as to spend more time with his family. Hall will remain in his current position until June 2023 or until his successor is appointed, if earlier.

07:27 EDT Stantec and Freese and Nichols awarded 5-year wastewater contract - Stantec and Freese and Nichols, a provider of water resources solutions' Stantec-Freese and Nichols JV has been awarded a five-year, $25M multiple award task order contract for architecture and engineering services by the U.S. Army Corps of Engineers Mobile District. Stantec-Freese and Nichols JV will provide the district's Water and Wastewater Technical Center of Expertise with planning, design, and construction phase services in support of the center's mission to deliver engineering solutions to secure the nation, energize the U.S. economy, and reduce disaster risk.

07:25 EDT PyroGenesis announces receipt of $1.3M payment from Client B - PyroGenesis Canada confirms that, further to its press release dated September 14, 2021, it has received a milestone payment from Client B of approximately $1.3M. Separately, the Company confirms that the previously announced trials of its patented plasma torch system for use in iron ore pelletization furnaces, with both Client A and Client B, are ongoing with no change in strategy by either PyroGenesis and/or the Clients. The names of the Clients have been kept confidential for competitive reasons. "These trials, representing years of research and development, computer modelling, business case development, and factory acceptance testing, have required multi-million-dollar infrastructure expenditures by the Clients," said P. Peter Pascali, CEO and Chair of PyroGenesis. "These projects are all continuing as expected notwithstanding the impact covid has had on our Client's ability to source the supplies required to ready their site for the introduction of our torches. Excluding covid-related supply chain delays on the Client's part, other engineering and project-partnership aspects not impacted by covid are continuing by both parties."

07:25 EDT Lithia & Driveway raises share repurchase authorization by $450M - Lithia & Driveway announced an increase of$450M to its share repurchase authorization by its Board of Directors, bringing total funds available for future repurchases to approximately$500M. Since the end of the third quarter, LAD has repurchased an additional, approximately, 175,000 shares for an average repurchase price of $198 per share. To date this year, LAD has repurchased over 2.4M shares, or over 8% of outstanding shares, for an average price of $276 per share.

07:24 EDT UPS plans to hire 60,000 of the seasonal employees it needs in one weekend - UPS said today it plans to hire at least 60,000 of the 100,000+ seasonal employees it needs for the holiday season in one weekend. UPS Brown Friday begins Nov. 4, with more than 450 in-person and virtual events scheduled across the country. "With major retailers announcing holiday deals long before Cyber Monday, it's more important than ever that we staff up now to meet the demands of the busy holiday shipping season," said Nando Cesarone, Executive Vice President and President, U.S. Operations. "We are well on our way to hiring the 100,000+ seasonal employees we announced in September, and UPS Brown Friday is a three-day sprint that helps us achieve that goal."

07:22 EDT Sonendo announces Health Canada approval to sell GentleWave G4 System - Sonendo announced that it has received Health Canada regulatory approval for commercial sales of its recently announced GentleWave G4 System, the next generation of its innovative technology platform designed to treat tooth decay. With Sonendo's patented technology at its core, the GentleWave G4 System is designed for an optimized doctor and patient experience with a refined, simplified workflow - all while delivering the enhanced level of clean that is only available with GentleWave Technology. Health Canada regulatory clearance expands Sonendo's suite of products available in Canada, allowing Sonendo to bring the GentleWave G4 System's modern design to the market, including an intuitive, user-friendly interface, battery backup and high-capacity fluid reservoirs, and multi-operatory connectivity. The approval for sale of the GentleWave G4 System follows the recent launch of the CleanFlow( procedure instrument in Canada. According to a recent clinical trial, 99.5% of patients experienced no pain during the GentleWave Procedure with the addition of CleanFlow Technology. "We are excited about introducing the GentleWave G4 System to our customers and the endodontic community in Canada," said Michael Smith, chief commercial officer at Sonendo. "We believe the GentleWave G4 System offers endodontic practices and their patients an elevated experience that also reinforces our commitment to commercial support and expansion in Canada."

07:22 EDT PharmaTher enters option agreement with Case Western Reserve University - PharmaTher Holdings announced that the Company has entered into an evaluation and exclusive option agreement with Case Western Reserve Universityin the development and commercialization for the intellectual property of ketamine in the treatment Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial for Rett syndrome and unpublished results will be evaluated to support a defined clinical and regulatory plan for FDA feedback. Under the terms of the Agreement, PharmaTher gained an exclusive option for up to 12 months to evaluate the regulatory, clinical development and commercialization plan for CWRU's intellectual property portfolio, which includes, US issued patent no. 11,213,494 and US provisional patent no. 62/312,749 entitled, "Composition and method for the treatment of pervasive development disorders", and US provisional patent no. 62/004,695 entitled, "Acute and sustained effects of low-dose ketamine treatment in mouse models of Rett Syndrome." Consistent with industry standards, PharmaTher paid a one-time fee for entering into the Agreement, and should the Company elect to exercise its option, both the Company and CWRU will negotiate a license agreement.

07:21 EDT XPO Logistics completes spin-off of RXO - XPO (XPO) announced that it has completed the previously announced spin-off of RXO (RXO), creating two independent, publicly traded companies. XPO shares will continue to trade on the New York Stock Exchange under the symbol "XPO" and, effective today, RXO will begin "regular way" trading on the NYSE under the symbol "RXO." Brad Jacobs, executive chairman of XPO, said, "With the spin-off complete, XPO and RXO have both launched from positions of strength as independent public companies. I want to thank the many people who have worked to make our strategic plan a success and created powerful new avenues for value creation." The separation was completed through a distribution to XPO stockholders of one share of RXO common stock for every one share of XPO common stock held as of the close of business on the record date for the distribution, October 20, 2022.

07:19 EDT Hexo files early warning report in respect of Zenabis Global - HEXO Corp. announced that, following the issuance of an approval and vesting order of the Superior Court of Quebec on October 24, 2022 in connection with previously initiated proceedings under the Companies' Creditors Arrangement Act relating to Zenabis Global and its direct and indirect wholly-owned subsidiaries, the Company no longer holds any shares, voting or equity securities or other interests in Zenabis or the Zenabis Group. HEXO understands that, as part of the pre-closing steps approved by the Zenabis Approval and Vesting Order, Zenabis amalgamated with certain other companies within the Zenabis Group to form Zenabis. Subsequently, all of the issued and outstanding shares of AmalCo then held by the Company as a result of such amalgamation were exchanged for common shares of a newly formed corporation and, immediately thereafter, all of the common shares of the capital of ResidualCo so held by the Company were cancelled for no consideration, as approved by the Zenabis Approval and Vesting Order. As a result of the foregoing, HEXO no longer holds any shares, voting or equity securities or other interests in any of the companies within the Zenabis Group, AmalCo or ResidualCo, and HEXO ultimately received no cash or other consideration for it so ceasing to hold any shares, voting or equity securities or other interests in Zenabis Global.

07:18 EDT Sirius XM continues to expect positive 2022 self-pay net subscriber additions

07:17 EDT Atlas Technical Consultants awarded $18M contract to remediate storage tanks - Atlas Technical Consultants announced that it has been awarded an $18 million contract to inspect and service a network of underground storage tanks for a public agency client. The contract, which was included in second quarter 2022 backlog, has an initial term of three years with two one-year extension options. Under the contract, Atlas engineers and technical staff will determine the extent of any release to the environment and develop plans to remediate any detected contamination to state-mandated cleanup levels. Atlas will be responsible for assessments, risk-based corrective actions, UST removals, design and installation of remediation systems, and site closure activities.

07:16 EDT Blucora to sell TaxAct for $720M, rebrand to Avantax - Blucora announced that it has agreed to sell TaxAct, its tax software business. Under the terms of the transaction, an affiliate of Cinven will purchase TaxAct for $720 million in cash, subject to adjustment. The transaction is expected to close by the end of 2022. Following completion of the transaction, Blucora will rebrand as Avantax and focus on its success in providing tax-focused wealth management through its independent broker dealer, Avantax Wealth Management, and its employee-based registered investment advisor, Avantax Planning Partners. As a pure-play wealth management company, Blucora will streamline its operations and cost structure, allowing the wealth business to invest further in areas that will generate strong revenue growth and expand its margins. Overall, the Company is expected to benefit from: A capital structure well-suited to invest in high-return initiatives, including: Building upon its successful recruiting efforts to attract new assets, Financial Professionals and accounting firms; Growing its RIA through on-platform firm acquisitions; and Creating best-in-class technology tools to meet the needs of financial professionals and clients. Enhanced returns on assets in a rising rate environment. The Company will continue to execute its differentiated tax-focused wealth management strategy that has delivered impressive results over the last few years including: Dramatically increased Financial Professional satisfaction; Exceptionally high production retention rates; Multiple quarters of positive net flows; and Sustained shifts toward advisory assets and its higher-margin employee-based RIA. Over the medium term, Blucora expects its pure-play broker-dealer and wealth management solutions business will achieve: v8.5% to 11% organic revenue CAGR; Strong positive net flows; and Adjusted EBITDA margins in 16-18% range The transaction is subject to customary closing conditions and regulatory approvals. The closing of the transaction is not subject to any financing condition. Blucora expects the transaction to deliver after-tax net cash proceeds of approximately $620 million.

07:14 EDT Newmont sees FY22 gold production 5.9M ounces - Sees FY22 total GEO production 7.2M ounces. Sees FY22 adjusted tax rate 30%-34%.

07:12 EDT Sealed Air acuires Liquibox for $1.5B, sees accretion - SEE announced that it has signed a definitive agreement to acquire Liquibox, beverage, consumer goods and industrial end-markets. This acquisition is highly complementary to Cryovac Fluids & Liquids business, the fastest growing area for SEE. Fluids & Liquids flexible packaging solutions are a $7 Billion addressable potential revenue opportunity with an attractive projected annual growth rate of approximately 6%. Liquibox has a strong financial profile and track record of growth and expects 2022 full year revenue and Adj. EBITDA of $362M and $85M respectively. SEE Operational Excellence in its integrated value chain for flexible packaging materials will provide significant productivity and efficiencies to achieve $30M in annualized estimated cost synergy savings by the end of year three (3). This transaction is a new opportunity to leverage SEE's proprietary M&A playbook to drive acquisitions to successful outcomes, as demonstrated with the recent case of Automated Packaging Systems...Purchase price of $1.15B on a cash-free debt-free basis represents an estimated EV/Adj. EBITDA multiple of 13.5x and a multiple of 10x after factoring in only cost synergies. SEE Adj. EPS, exclusive of purchase accounting, will be accretive immediately after close. SEE has secured $1.0B of committed debt financing with the balance of the consideration to be paid with cash on hand. As of September 30, 2022, SEE had $1.4B of liquidity consisting of $1.1B available under our committed credit facilities and $249M in cash.

07:06 EDT LGI Homes cuts FY22 home closings view to 6,700-7,100 from 7,500-8,300 - Active selling communities at the end of 2022 between 95 and 100; Average sales price per home closed between $340,000 and $350,000; Gross margin as a percentage of home sales revenues between 27.7% and 28.7%; Adjusted gross margin as a percentage of home sales revenues between 29.0% and 30.0% with capitalized interest accounting for substantially all the difference between gross margin and adjusted gross margin as a percentage of home sales revenues; SG&A as a percentage of home sales revenues between 11.0% and 12.0%; Effective tax rate between 21.0% and 22.0%.

07:03 EDT Atlas Corp. to be acquired by Poseidon Acquisition Corp. for $15.50 per share

06:58 EDT Uber sees Q4 gross bookings up 23%-27% y/y - For Q4, Uber anticipates: Gross Bookings to grow 23% to 27% YoY on a constant currency basis, with an expected 7 percentage point YoY currency headwind, translating to a range of $30.0 billion to $31.0 billion; Adjusted EBITDA of $600 million to $630 million.

06:49 EDT Quest Diagnostics completes CEO succession - Quest Diagnostics announced that Jim Davis has succeeded Steve Rusckowski as the CEO and president of Quest Diagnostics, completing a transition first announced on February 3. In addition, Davis has been elected to the company's board of directors, expanding the board from nine to 10 directors. Rusckowski, who has served as CEO and president since May 2012, remains chairman of the company's board of directors through March 2023.

06:41 EDT Pfizer reports 'positive' results from Phase 3 trial of PF-06928316 - Pfizer announced positive top-line data from the Phase 3 clinical trial MATISSE investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth. The pre-planned, interim efficacy analysis conducted by an external and independent Data Monitoring Committee met the success criterion for one of two primary endpoints. The observed efficacy for severe medically attended lower respiratory tract illness was 81.8% (CI: 40.6%, 96.3%) through the first 90 days of life. Substantial efficacy of 69.4% (CI: 44.3%, 84.1%) was demonstrated for infants over the six-month follow-up period. Although the statistical success criterion was not met for the second primary endpoint, clinically meaningful efficacy was observed for MA-LRTI of 57.1% (CI: 14.7%, 79.8%) in infants from birth through the first 90 days of life. Efficacy for MA-LRTI of 51.3% (CI: 29.4%, 66.8%) was observed over the six-month follow up period. Pre-planned safety reviews conducted at regular intervals throughout the duration of the study by the DMC also indicate the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

06:38 EDT BP sees 2022 upstream production slightly higher than 2021 - The company said, "bp now expects reported upstream production to be slightly higher compared with 2021 despite the absence of production from our Russia incorporated joint ventures. On an underlying basis, we expect upstream production to be higher. bp continues to expect the other businesses & corporate underlying annual charge to be in a range of $1.2-1.4 billion for 2022. The charge may vary from quarter to quarter. bp continues to expect the depreciation, depletion and amortization to be at a similar level to 2021. The underlying ETR for 2022 is expected to be around 35% but is sensitive to the impact that volatility in the current price environment may have on the geographical mix of the group's profits and losses. bp now expects capital expenditure of around $15.5 billion in 2022, if the acquisition of Archaea Energy completes before year end. bp now expects divestment and other proceeds to be slightly over $3 billion in 2022. Against a target of $25 billion of divestment and other proceeds between the second half of 2020 and 2025 bp has now received $15.3 billion of proceeds. bp continues to expect Gulf of Mexico oil spill payments for the year to be around $1.4 billion pre-tax including the $1.2 billion pre-tax paid during the second quarter. For 2022, and subject to maintaining a strong investment grade credit rating, bp remains committed to using 60% of surplus cash flow for share buybacks and intends to allocate the remaining 40% to further strengthen the balance sheet. On average, based on bp's current forecasts, at around $60 per barrel Brent and subject to the board's discretion each quarter, bp continues to expect to be able to deliver share buybacks of around $4.0 billion per annum and have capacity for an annual increase in the dividend per ordinary share of around 4% through 2025."

06:35 EDT Lear reports Q3 adjusted EPS $2.33, consensus $2.12 - Reports Q3 revenue $5.24B, consensus $5.14B. "Lear delivered improved financial results in the third quarter, reflecting higher industry volumes and our strong new business backlog," said Ray Scott, Lear's president and CEO. "We expect further improvement in both business segments in the fourth quarter. We continue to win electrification awards in E-Systems, highlighted by our most significant award to date to supply our BDU across all full-size SUVs and trucks built on General Motors' Ultium EV battery platform through 2030. In Seating, we once again won more than twice as many J.D. Power seat quality awards than any other seating supplier. We continue to focus our efforts on operational efficiencies, developing innovative solutions for our customers, and increasing earnings and cash flow."

06:34 EDT Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash - Johnson & Johnson (JNJ) and Abiomed (ABMD) announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed, for an upfront payment of $380.00 per share in cash, corresponding to an enterprise value of approximately $16.6B which includes cash acquired. Abiomed shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. The transaction was unanimously approved by both companies' boards of directors. Under the terms of the agreement, a wholly owned subsidiary of Johnson & Johnson will commence a tender offer for all outstanding shares of Abiomed, whereby Abiomed stockholders will be offered an upfront payment of $380.00 per share in cash, along with one non-tradeable CVR that entitles them to up to an additional $35.00 per share in cash if certain clinical and commercial milestones are achieved. The milestones consist of: $17.50 per share, payable if net sales for Abiomed products exceeds $3.7 billion during Johnson & Johnson's fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson & Johnson's fiscal first quarter of 2029, $8.75 per share; $7.50 per share payable upon FDA premarket application approval of the use of Impella products in STEMI patients without cardiogenic shock by January 1, 2028; and $10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029. Johnson & Johnson expects to fund the transaction through a combination of cash on hand and short-term financing. Following the completion of the transaction, Abiomed will operate as a standalone business within Johnson & Johnson MedTech. Michael R. Minogue, Abiomed's Chairman, President and Chief Executive Officer has an established succession plan to sustain a strong future and will assist in the transition. Andrew Greenfield, who has 17 years with Abiomed, most recently serving as Chief Commercial Officer has been appointed President of Abiomed. Michael Bodner will lead the integration. The transaction is expected to be completed prior to the end of the first quarter of 2023 and is conditioned on the tender of a majority of the outstanding shares of Abiomed's common stock, as well as the receipt of applicable regulatory approvals and other customary closing conditions.

06:32 EDT J&J: Abiomed acquisition has enterprise value of $16.6B

06:31 EDT Johnson & Johnson to buy Abiomed for upfront payment of $380 per share in cash

06:31 EDT Johnson & Johnson to acquire Abiomed for $380 per share in cash

06:27 EDT CenterPoint Energy promotes CFO Jason Wells to COO - CenterPoint Energy promoted Jason Wells, Executive VP and CFO, to the role of President and COO, effective January 1, 2023. Dave Lesar will continue to serve as CEO. The company is initiating a public search for a CFO and Wells will continue to serve in his current capacity until his successor has been appointed.

06:17 EDT Easterly Government Properties to sell 10-property portfolio - Easterly Government Properties announced that it has sold or agreed to sell, subject to customary closing conditions, 10 of its primarily government leased assets representing a combined total of approximately 668,000 leased square feet for approximately $205.3M. At the quarter ended September 30, 2022, the Disposition Portfolio's attributes include: 10 buildings totaling approximately 668,000 leased square feet with a weighted average age of 14.0 years; 99% leased to the U.S. Government with a weighted average remaining lease term 7.9 years. The sale of the Disposition Portfolio will increase the weighted average lease term of the company's overall portfolio. The sale of nine of the 10 assets in the Disposition Portfolio closed on October 27. Subject to the satisfaction of customary closing conditions, the sale of the remaining asset, DOI - Billings, is expected to close in late December.

06:15 EDT Digihost reports October Bitcoin up 78% year-over-year - Digihost Technology provided unaudited comparative BTC production results for October 2022, combined with an operations update. The company mined 74.58 BTC in October, vs. 41.84 BTC in October 2021, an increase of 32.74 BTC or approximately 78%. Total holdings were 118.16 BTC at the end of October, valued at approximately $2.45M based on a BTC price of $20,705 as of October 31. Ethereum holdings were 800.89 ETH at the end of October valued at approximately $1.29M. Total digital asset inventory value of BTC and ETH was approximately $3.74M as of October 31, 2022. In addition, the company held cash of approximately $3.42M at the end of October. Cash and liquid assets as of October 31, 2022 totalled approximately $7.16M vs. cash and liquid assets of approximately $7.46M as of September 30, 2022. The company sold a portion of its BTC production during October to fully fund its energy costs. Natural gas prices declined approximately 25% during the month of October. The Company continues to remain debt free as of October 31. The company's mining operations continue to remain cash flow positive. The Alabama Phase 1 build-out is continuing on schedule and on budget. Phase 1, scheduled for completion in Q4 of 2022, will provide the Company with 22MW of power capacity resulting in additional mining capacity of approximately 550 PH. When coupled with the incremental mining capacity from the NT power plant, Digihost's total computing power by the end of Q4 could reach up to approximately 2.2 EH.

06:10 EDT Similarweb and EDO partner for convergent TV measurements - Similarweb announced a new collaboration with EDO, the data and analytics platform that measures predictive outcomes for Convergent TV - the unification of streaming and traditional linear TV. The alliance will produce a scaled solution for CTV measurement. EDO will receive internet activity data from Similarweb hourly and match and measure lift in digital behaviors with the over half a billion impressions per day EDO observes across all of linear and streaming TV. The insights learned from this collaboration will aim to help brands, agencies, and networks know which solutions work and how to best maximize consumer engagement. It will also expand EDO's existing consumer engagement dataset for OTT, increasing the number of surveyed household panels from the hundreds of thousands to the millions. Similarweb's web insights and analytics will enable EDO to identify which ads are viewed by households in a targeted geographic area and what the resulting consumer behavior is after viewing the ads, aiming to reveal previously unavailable granular measurement insights for clients.

06:08 EDT Louisiana-Pacific sees FY22 capital expenditures $400M-$420M - Sees Q4 adjusted EBITDA $100M.

06:06 EDT Standard Lithium issued two U.S. patents for lithium recovery processes - Standard Lithium announced that the USPTO has issued Notices of Allowance for Standard Lithium's first two U.S. patent applications, both titled "Process for Recovering Lithium from Brines", a novel and proprietary technique for continuous Direct Lithium Extraction from lithium brines. These U.S. patent applications are two of the three pending U.S. patent applications for elements of Standard Lithium's DLE processes. Standard Lithium anticipates the issue of the formal registration of these patents in the coming months.

06:04 EDT Elon Musk ousts Twitter board, named sole director - Twitter said in a securities filing Monday that the nine members of its former board are no longer directors as of the consummation of the $44B merger, which closed last week. Elon Musk, now the company's CEO, is serving as Twitter's sole director, according to the filing.

05:56 EDT Elon Musk is CEO of post-merger company after Twitter deal - According to a regulatory filing, Elon Musk will be the CEO of Twitter, which he recently acquired for $44B. Musk previously changed his Twitter bio to "Chief Twit" and said he had "no idea who the CEO is."

05:40 EDT Twitter's Roth: Content moderation freeze 'exactly what we should be doing' - Yoel Roth, Twitter's head of safety and integrity, responded to reports that the company has frozen some employee access to internal tools used for content moderation and other policy enforcement, by saying: "This is exactly what we (or any company) should be doing in the midst of a corporate transition to reduce opportunities for insider risk. We're still enforcing our rules at scale." Reference Link

05:32 EDT Xpeng delivers 5,101 Smart EVs in October - XPeng announced its vehicle delivery results for October. XPeng recorded monthly deliveries in October of 5,101 Smart EVs, consisting of 2,104 P7s, the company's smart sports sedan, 1,665 P5 smart family sedans and 709 G3i smart compact SUVs. October deliveries also included 623 G9 SUVs, the company's fourth production model launched in September. Mass deliveries of the G9 began on October 27, reaching customers in over 100 cities across China.

05:14 EDT Standard Lithium announces notices of allowance for two U.S. patent applications - Standard Lithium announced that the United States Patent and Trademark Office, or USPTO, has issued notices of allowance for Standard Lithium's first two U.S. patent applications; serial no.16/410,523 and serial no. 16/224/463, both titled "Process for Recovering Lithium from Brines", a novel and proprietary technique for continuous Direct Lithium Extraction, or DLE, from lithium brines. These U.S. patent applications are two of the three pending U.S. patent applications for elements of Standard Lithium's innovative DLE processes. A notice of allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. Standard Lithium anticipates the issue of the formal registration of these patents in the coming months.

05:10 EDT Li Auto delivers 10,052 vehicles in October, up 31.4% - Li Auto announced that the company delivered 10,052 vehicles in October, up 31.4% year over year. The cumulative deliveries of Li Auto vehicles reached 221,067 as of the end of October. "Since its launch, Li L8 has received positive user feedback and wide recognition, off to a strong start with continued increase in orders. We will officially commence delivery of Li L8 this month. Separately, orders for Li L9 remained robust and the level of its user satisfaction continued to exceed their expectations, further solidifying our market position in the RMB400,000 and higher segment," commented Yanan Shen, co-founder and president of Li Auto.